Page last updated: 2024-11-05

tranexamic acid and Complication, Postoperative

tranexamic acid has been researched along with Complication, Postoperative in 218 studies

Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.

Research Excerpts

ExcerptRelevanceReference
"Dexamethasone and tranexamic acid are used to decrease post-rhinoplasty periorbital edema and ecchymosis."9.27Comparison of the Effect of Dexamethasone and Tranexamic Acid, Separately or in Combination on Post-Rhinoplasty Edema and Ecchymosis. ( Bijani, A; Ghanepur, H; Ghassemi, A; Khakzad, M; Mehdizadeh, M; Mehrbakhsh, Z; Mir, M; Moghadamnia, A; Nekoohesh, L, 2018)
"The aim of this study was to investigate the efficacy of tranexamic acid (TA) and methylprednisolone on periorbital edema, ecchymosis, and intraoperative bleeding in patients who underwent open septorhinoplasty (oSRP)."9.20The efficacy of tranexamic acid and corticosteroid on edema and ecchymosis in septorhinoplasty. ( Akyiğit, A; Düzer, S; Orhan, İ; Polat, C; Sakallioğlu, Ö; Soylu, E, 2015)
"To systematically review the literature to compare the efficacy and safety of tranexamic acid (TXA) as a means to minimize hemarthrosis-related complications after arthroscopic procedures of the knee, hip, and shoulder."9.12Tranexamic Acid Use in Knee and Shoulder Arthroscopy Leads to Improved Outcomes and Fewer Hemarthrosis-Related Complications: A Systematic Review of Level I and II Studies. ( Belk, JW; Dragoo, JL; Houck, DA; McCarty, EC; Savoie, FH; Thon, SG, 2021)
"This study aimed to evaluate the efficacy and safety of using high-dose intravenous tranexamic acid (TXA) to reduce blood loss in idiopathic scoliosis surgery."9.12The efficacy and safety of high-dose tranexamic acid in adolescent idiopathic scoliosis: a meta-analysis. ( Chen, JC; Lin, L; Na, XQ; Qu, QC; Ruan, TY; Shrestha, IK; Si, YY; Tan, M; Tao, JP, 2021)
"A randomized double-blind trial has shown that, in 160 women with breast cancer undergoing lumpectomy or mastectomy with axillary clearance, perioperative and postoperative administration of tranexamic acid 1 g three times daily resulted in a significant reduction in the mean postoperative drainage volume compared with patients given placebo (283 versus 432 ml, P < 0."9.07Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer. ( Haberthuer, F; Harder, F; Kreuter, U; Laffer, U; Oertli, D, 1994)
"A randomized, controlled clinical trial was carried out to study the effect of tranexamic acid (AMCA, trans-AMCHA) in prevention of early rebleeding after proven rupture of an intracranial aneurysm."9.04Tranexamic acid in the preoperative management of ruptured intracranial aneurysms. ( Fodstad, H; Liliequist, B; Schannong, M; Thulin, CA, 1978)
"The influence of tranexamic acid on the intraocular pressure and central corneal thickness has been examined by means of a double-blind trial in patients with glaucoma simplex."9.04A double-blind study on the influence of tranexamic acid on the intraocular pressure and the central corneal thickness after trabeculectomy for glaucoma simplex. ( Bramsen, T, 1978)
"To systematically examine the role of tranexamic acid in reducing intraoperative blood loss and postoperative edema and ecchymosis among patients undergoing primary elective rhinoplasty."9.01Role of Tranexamic Acid in Reducing Intraoperative Blood Loss and Postoperative Edema and Ecchymosis in Primary Elective Rhinoplasty: A Systematic Review and Meta-analysis. ( Bezuhly, M; McGuire, C; Nurmsoo, S; Samargandi, OA, 2019)
"To investigate the results of tranexamic acid use to reduce intraoperative bleeding, postoperative eyelid edema, and periorbital ecchymosis in rhinoplasty."8.98Preoperative Tranexamic Acid for Treatment of Bleeding, Edema, and Ecchymosis in Patients Undergoing Rhinoplasty: A Systematic Review and Meta-analysis. ( de Aguiar Menezes, MV; de Souza Dantas, R; de Vasconcellos, SJA; do Nascimento-Júnior, EM; Martins-Filho, PRS; Tavares Mendes, ML, 2018)
"Previous studies have shown that systemic tranexamic acid reduces bleeding during soft tissue surgeries and reduces postoperative ecchymosis and edema experienced by surgical patients."8.02Effect of Tranexamic Acid Administration on Postoperative Ecchymosis and Edema in Excision of Lipomas. ( Choi, YJ; Kim, WS; Lee, GY; Lee, HJ; Park, HJ, 2021)
"The aim of the present study is to examine the effect of local administration of tranexamic acid (TXA) through lateral osteotomy line on postoperative periorbital edema and ecchymosis."8.02The Effects of Intraoperative Local Tranexamic Acid on Periorbital Edema and Ecchymosis in Septorhinoplasty. ( Bezgin, SÜ; Çakabay, T; Çelebi, Ş; İpek, HD, 2021)
"Intravenous tranexamic acid safely reduces risk of hematoma in implant-based breast reconstruction."7.96Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events. ( Banuelos, J; Harless, CA; Jacobson, SR; Manrique, OJ; Martinez-Jorge, J; Nguyen, MT; Tran, NV; Weissler, JM, 2020)
"Forty-six patients receiving endobronchial ε-aminocaproic acid for the treatment or prevention of pulmonary bleeding."7.96Bronchoscopic delivery of aminocaproic acid as a treatment for pulmonary bleeding: A case series. ( Oromendia, C; Rajwani, K; Ramos, LG; Sanso, LM; Simon, RP, 2020)
"Tranexamic acid (AMCA) is an inhibitor of fibrinolysis used to treat fibrinolytic bleeding (e."7.68Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. ( Astedt, B; Lindoff, C; Rybo, G, 1993)
"Tranexamic acid (TXA) is an antifibrinolytic drug that has been shown to reduce blood loss following surgery."5.91Intravenous tranexamic acid is associated with an increased risk of pulmonary embolism following sarcoma resection. ( Foster, D; Garner, H; Goulding, K; Houdek, M; Sebro, R; Spaulding, AC; Stanborough, R; Wilke, B, 2023)
"High-dose tranexamic acid is more effective in reducing blood loss and blood transfusion without increasing the risk of postoperative complications."5.69Intraoperative use of tranexamic acid to reduce blood loss during cytoreductive surgery for advanced ovarian cancer: A randomized controlled clinical trial. ( Chai, M; He, Z; Wu, X; Xia, L; Yang, X; Zhang, J, 2023)
"To assess the efficacy and safety of single-dose tranexamic acid on the blood transfusion rate and outcomes of patients with complex kidney stones undergoing percutaneous nephrolithotomy (PCNL)."5.51Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomised, double-blinded, placebo-controlled trial. ( Batagello, CA; Coelho, RF; Danilovic, A; Marchini, GS; Mazzucchi, E; Miller, AW; Monga, M; Nahas, WC; Srougi, M; Torricelli, FCM; Vicentini, FC, 2022)
"Tranexamic acid (TXA) is a commonly antifibrinolytic agent in cardiac surgeries with cardiopulmonary bypass (CPB), however, there is concern that it might increase incidence of stroke after cardiac surgery."5.46Intraoperative tranexamic acid is associated with postoperative stroke in patients undergoing cardiac surgery. ( Huo, YF; Sun, K; Sun, LH; Xing, XF; Yan, M; Yu, LN; Yu, YX; Zhang, FJ; Zhou, ZF, 2017)
"Compared to the non-seizure group, seizure patients had an increased rate of postoperative neurological complications, defined as delirium and/or stroke (3."5.38Seizures following cardiac surgery: the impact of tranexamic acid and other risk factors. ( Ariano, RE; Grocott, HP; Jacobsohn, E; Leake, J; Manji, JS; Manji, RA; Menkis, AH, 2012)
"Postoperative seizures occurred significantly more frequently in TXA patients (7."5.37Seizures after open heart surgery: comparison of ε-aminocaproic acid and tranexamic acid. ( Breuer, T; Gertler, R; Knorr, J; Lange, R; Macguill, M; Martin, K; Tassani, P; Wiesner, G, 2011)
"The exact mechanism of TxA-induced seizures is thought to be via inhibition of gamma-aminobutyric acid receptors in neurons."5.36Tranexamic Acid in cardiac surgery and postoperative seizures: a case report series. ( Almeida, A; Bell, D; Marasco, S; Rowland, M, 2010)
"All patients with seizures did not have permanent neurological abnormalities."5.36High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients. ( Burt, C; Chu, M; Falter, F; Granton, J; Murkin, JM; Young, B, 2010)
"We examined the blood conserving effect of tranexamic acid in total hip arthroplasty using the direct anterior approach with enoxaparin as deep vein thrombosis (DVT) chemoprophylaxis, and whether this translates to an effect on functional outcomes in the perioperative period."5.30OBTAIN E: outcome benefits of tranexamic acid in hip arthroplasty with enoxaparin: a randomised double-blinded controlled trial. ( Duggan, J; Duncan, S; Fraval, A; Murray, T; Tirosh, O; Tran, P, 2019)
"Dexamethasone and tranexamic acid are used to decrease post-rhinoplasty periorbital edema and ecchymosis."5.27Comparison of the Effect of Dexamethasone and Tranexamic Acid, Separately or in Combination on Post-Rhinoplasty Edema and Ecchymosis. ( Bijani, A; Ghanepur, H; Ghassemi, A; Khakzad, M; Mehdizadeh, M; Mehrbakhsh, Z; Mir, M; Moghadamnia, A; Nekoohesh, L, 2018)
"The aim of this randomized double-blind study was to evaluate the efficacy of Tranexamic acid (TXA) on intraoperative bleeding, postoperative eyelid edema, and postoperative periorbital ecchymosis in rhinoplasty."5.24Efficacy of tranexamic acid on side effects of rhinoplasty: A randomized double-blind study. ( Chavoshzadeh, MA; Ghavimi, MA; Ghoreishizadeh, A; Taheri Talesh, K; Zarandi, A, 2017)
"Tranexamic acid reduces the risk of bleeding among patients undergoing cardiac surgery, but it is unclear whether this leads to improved outcomes."5.24Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery. ( Bussières, JS; Byrne, K; Chan, MT; Cooper, DJ; Forbes, A; Jayarajah, M; Landoni, G; Marasco, S; McGuinness, S; McNeil, J; Myles, PS; Painter, T; Silbert, B; Smith, JA; Wallace, S, 2017)
"The aim of this study was to investigate the efficacy of tranexamic acid (TA) and methylprednisolone on periorbital edema, ecchymosis, and intraoperative bleeding in patients who underwent open septorhinoplasty (oSRP)."5.20The efficacy of tranexamic acid and corticosteroid on edema and ecchymosis in septorhinoplasty. ( Akyiğit, A; Düzer, S; Orhan, İ; Polat, C; Sakallioğlu, Ö; Soylu, E, 2015)
"There was no statistically significant reduction in bleeding volume with the use of tranexamic acid (mean ± standard deviation, 135."5.16Tranexamic acid in adenotonsillectomy in children: a double-blind randomized clinical trial. ( Brum, MR; Castro, SF; Lima, LH; Lubianca Neto, JF; Machado, GM; Miura, MS, 2012)
"To systematically review the literature to compare the efficacy and safety of tranexamic acid (TXA) as a means to minimize hemarthrosis-related complications after arthroscopic procedures of the knee, hip, and shoulder."5.12Tranexamic Acid Use in Knee and Shoulder Arthroscopy Leads to Improved Outcomes and Fewer Hemarthrosis-Related Complications: A Systematic Review of Level I and II Studies. ( Belk, JW; Dragoo, JL; Houck, DA; McCarty, EC; Savoie, FH; Thon, SG, 2021)
"This study aimed to evaluate the efficacy and safety of using high-dose intravenous tranexamic acid (TXA) to reduce blood loss in idiopathic scoliosis surgery."5.12The efficacy and safety of high-dose tranexamic acid in adolescent idiopathic scoliosis: a meta-analysis. ( Chen, JC; Lin, L; Na, XQ; Qu, QC; Ruan, TY; Shrestha, IK; Si, YY; Tan, M; Tao, JP, 2021)
"A randomized double-blind trial has shown that, in 160 women with breast cancer undergoing lumpectomy or mastectomy with axillary clearance, perioperative and postoperative administration of tranexamic acid 1 g three times daily resulted in a significant reduction in the mean postoperative drainage volume compared with patients given placebo (283 versus 432 ml, P < 0."5.07Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer. ( Haberthuer, F; Harder, F; Kreuter, U; Laffer, U; Oertli, D, 1994)
"The contribution of fibrinolysis to postoperative bleeding after cardiopulmonary bypass led to routine use of tranexamic acid, a potent antifibrinolytic drug, for a period of time."5.07Tranexamic acid (Cyklokapron) is not necessary to reduce blood loss after coronary artery bypass operations. ( Abdelnoor, M; Am Holen, E; Ovrum, E; Oystese, R; Ringdal, ML, 1993)
"One hundred patients with a verified subarachnoid haemorrhage were studied in a double blind, placebo-controlled trial at a single centre to determine the value and relative risks of tranexamic acid (TXA) in the management of ruptured intracranial aneurysms."5.06Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study. ( Hitchcock, ER; Meyer, CH; Tsementzis, SA, 1990)
"A randomized, controlled clinical trial was carried out to study the effect of tranexamic acid (AMCA, trans-AMCHA) in prevention of early rebleeding after proven rupture of an intracranial aneurysm."5.04Tranexamic acid in the preoperative management of ruptured intracranial aneurysms. ( Fodstad, H; Liliequist, B; Schannong, M; Thulin, CA, 1978)
"The influence of tranexamic acid on the intraocular pressure and central corneal thickness has been examined by means of a double-blind trial in patients with glaucoma simplex."5.04A double-blind study on the influence of tranexamic acid on the intraocular pressure and the central corneal thickness after trabeculectomy for glaucoma simplex. ( Bramsen, T, 1978)
"To systematically examine the role of tranexamic acid in reducing intraoperative blood loss and postoperative edema and ecchymosis among patients undergoing primary elective rhinoplasty."5.01Role of Tranexamic Acid in Reducing Intraoperative Blood Loss and Postoperative Edema and Ecchymosis in Primary Elective Rhinoplasty: A Systematic Review and Meta-analysis. ( Bezuhly, M; McGuire, C; Nurmsoo, S; Samargandi, OA, 2019)
"To investigate the results of tranexamic acid use to reduce intraoperative bleeding, postoperative eyelid edema, and periorbital ecchymosis in rhinoplasty."4.98Preoperative Tranexamic Acid for Treatment of Bleeding, Edema, and Ecchymosis in Patients Undergoing Rhinoplasty: A Systematic Review and Meta-analysis. ( de Aguiar Menezes, MV; de Souza Dantas, R; de Vasconcellos, SJA; do Nascimento-Júnior, EM; Martins-Filho, PRS; Tavares Mendes, ML, 2018)
" A combination of aprotinin with tranexamic acid may be effective in preventing or delaying rebleeding after rupture of an intracerebral aneurysm; the addition of aprotinin seems to decrease the incidence of delayed cerebral vasospasm and ischaemic complications which are sometimes noted when tranexamic acid alone is used."4.77Clinical application of inhibitors of fibrinolysis. ( Verstraete, M, 1985)
"The purpose of this study was to explore efficacy of locally injected tranexamic acid (TXA) at a concentration of 1 mg/mL for reduction perioperative bleeding and postoperative complications in subcutaneous tumor excisions."4.31Efficacy of local infiltration of tranexamic acid in subcutaneous surgery: A protocol from a single medical center. ( Chang, YJ; Lin, HC; Lin, YH; Wang, PL, 2023)
"The aim of the present study is to examine the effect of local administration of tranexamic acid (TXA) through lateral osteotomy line on postoperative periorbital edema and ecchymosis."4.02The Effects of Intraoperative Local Tranexamic Acid on Periorbital Edema and Ecchymosis in Septorhinoplasty. ( Bezgin, SÜ; Çakabay, T; Çelebi, Ş; İpek, HD, 2021)
"The specific method and dose of tranexamic acid (TXA) topically applied for intertrochanteric fractures have not been well established."4.02Effect and safety of topical application of tranexamic acid to reduce perioperative blood loss in elderly patients with intertrochanteric fracture undergoing PFNA. ( He, J; Huang, T; Wei, H; Xia, M; Xian, S; Xiao, Q; Xu, W, 2021)
"Previous studies have shown that systemic tranexamic acid reduces bleeding during soft tissue surgeries and reduces postoperative ecchymosis and edema experienced by surgical patients."4.02Effect of Tranexamic Acid Administration on Postoperative Ecchymosis and Edema in Excision of Lipomas. ( Choi, YJ; Kim, WS; Lee, GY; Lee, HJ; Park, HJ, 2021)
" A standard blood management protocol that consisted of hypotensive anesthesia, local and systemic administration of tranexamic acid (TXA) and intraoperative cell salvage was applied to all patients."3.96Does tourniquet use decrease blood loss following primary total knee arthroplasty in Jehovah's Witness patients? ( Çıtak, M; Gehrke, T; Köse, Ö; Levent, A; Linke, P, 2020)
"Intravenous tranexamic acid safely reduces risk of hematoma in implant-based breast reconstruction."3.96Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events. ( Banuelos, J; Harless, CA; Jacobson, SR; Manrique, OJ; Martinez-Jorge, J; Nguyen, MT; Tran, NV; Weissler, JM, 2020)
"Forty-six patients receiving endobronchial ε-aminocaproic acid for the treatment or prevention of pulmonary bleeding."3.96Bronchoscopic delivery of aminocaproic acid as a treatment for pulmonary bleeding: A case series. ( Oromendia, C; Rajwani, K; Ramos, LG; Sanso, LM; Simon, RP, 2020)
"Geriatric hip fracture patients are particularly susceptible to blood loss and venous thromboembolism (VTE) during hemiarthroplasty, yet relatively few studies have examined the safety and efficacy of tranexamic acid (TXA) in these patients."3.91Efficacy and safety of tranexamic acid in geriatric hip fracture with hemiarthroplasty: a retrospective cohort study. ( Chen, G; Hu, Q; Huang, Q; Pei, F; Xie, J; Zhou, Z, 2019)
"Tranexamic acid (AMCA) is an inhibitor of fibrinolysis used to treat fibrinolytic bleeding (e."3.68Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. ( Astedt, B; Lindoff, C; Rybo, G, 1993)
"The effects of locally deposited fibrin and of tranexamic acid-induced antifibrinolysis on forming granulation tissue were studied in the light of a recently developed method for treatment of postoperative fistulas by occlusion with a fibrin clot."3.67Effects of tranexamic acid and local fibrin deposition of fibrinolysis and granulation tissue formation in preformed cavities. ( Hedelin, H; Peterson, HI; Pettersson, S; Teger-Nilsson, AC, 1984)
" Prophylaxis against angioneurotic oedema using danazol and tranexamic acid is described and the resultant complication of mesenteric venous thrombosis reported."3.67Acquired C1 esterase inhibitor deficiency. ( Coulson, IH; Findley, IL; Gould, TR; Razis, PA, 1986)
"Tranexamic acid (TXA) has been hypothesized as an oral agent to avoid CSDH progression and/or recurrence."3.30Effect of postoperative tranexamic acid on recurrence rate and complications in chronic subdural hematomas patients: preliminary results of a randomized controlled clinical trial. ( de Freitas, PVV; de Oliveira, MF; de Paula, MVCT; Melo, MM; Pahl, FH; Ribeiro, BDC; Rotta, JM, 2023)
"Secondary outcome criteria were postoperative pain, intraarticular effusion (measured by ultrasound), range of motion (ROM) at discharge, peri- and postoperative complications and the KOOS PS (pre- and postoperatively at 1 year follow up)."3.11Use of tranexamic acid in medial open wedge high tibial osteotomy. ( Bentzin, M; Bierke, S; Häner, M; Park, HU; Petersen, W, 2022)
"Tranexamic acid (TXA) is an antifibrinolytic agent, which reduces bleeding in numerous scenarios, however, its prophylactic use in mitigating post-TBLB bleeding has not been investigated."2.94Prophylactic use of tranexamic acid for prevention of bleeding during transbronchial lung biopsies - A randomized, double-blind, placebo-controlled trial. ( Abu Rmeileh, A; Abutbul, A; Berkman, N; Cohen Goichman, P; Fridlender, ZG; Huszti, E; Kuint, R; Levy, L; Shriki, O, 2020)
"Deep venous thrombosis (DVT) and pulmonary embolism (PE) events were monitored and recorded."2.94Combined use of intravenous and topical tranexamic acid efficiently reduces blood loss in patients aged over 60 operated with a 2-level lumbar fusion. ( Bai, T; Huang, Y; Li, J; Liu, Y; Wang, L, 2020)
"Tranexamic acid (TXA) has long been used to reduce blood loss associated with total knee arthroplasty (TKA)."2.90Comparison of oral vs. combined topical/intravenous/oral tranexamic acid in the prevention of blood loss in total knee arthroplasty: A randomised clinical trial. ( Bernaitis, N; Dare, W; King, L; Randle, R, 2019)
"Tranexamic acid (TXA) is an antifibrinolytic drug."2.90Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels. ( Baaklini, LR; Cross, JR; Fields, KG; Jules-Elysee, KM; Mayman, DJ; McLawhorn, AS; Pickard, AJ; Qin, W; Sculco, TP; Su, EP; Tseng, A, 2019)
" However, the optimal oral dosage regimen to achieve maximum blood-loss reduction remains unclear."2.90Finding the Optimal Regimen for Oral Tranexamic Acid Administration in Primary Total Hip Arthroplasty: A Randomized Controlled Trial. ( Luo, ZY; Pei, FX; Wang, D; Wang, HY; Zeng, WN; Zhou, ZK, 2019)
"No episodes of transfusion, pulmonary embolism, or major bleeding occurred in either group."2.84Comparison of Enoxaparin and Rivaroxaban in Balance of Anti-Fibrinolysis and Anticoagulation Following Primary Total Knee Replacement: A Pilot Study. ( Huang, Q; Ma, J; Pei, F; Xie, J; Yue, C, 2017)
"Tranexamic acid was given at the end of the operation and 3 hours later."2.69Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty. ( Benoni, G; Fredin, H; Lethagen, S; Nilsson, P, 2000)
"Tranexamic acid was found as effective as aprotinin on platelets function."2.67[The use of antifibrinolytics in heart surgery. 3 prospective studies]. ( Benmosbah, L; Boughenou, F; Cousin, MT; Madi-Jebara, S; Massonnet-Vastel, S, 1993)
" It was concluded that patients on oral anticoagulants can undergo oral surgery within the therapeutic range without reducing the dosage of anticoagulants, provided that local antifibrinolytic treatment with tranexamic acid solution is instituted."2.67Prevention of postsurgical bleeding in oral surgery using tranexamic acid without dose modification of oral anticoagulants. ( Alander, U; Blombäck, M; Hall, G; Ramström, G; Sindet-Pedersen, S, 1993)
"Fifteen extraction sockets packed with a new drug combination which includes a local anaesthetic (cincain chloride), a local antiseptic (tri-iodomethane) and two drugs with a potent antifibrinolytic activity (tranexamic acid and propyl-hydroxy-benzoic acid) in an absorbable gelatin sponge (Gelfoam) as a vehicle, were histologically assessed with special reference to the parameters related to wound healing."2.65The effects on extraction wound healing of a new drug combination introduced for use in the prevention of post-extraction complications. A preliminary report. ( Syrjänen, KJ; Syrjänen, SM, 1981)
"placebo on development of alveolitis sicca dolorosa (ASD) had as preoperative registration requirements age, sex, use of oral contraceptives, menstrual cycle, smoking, and degree of impaction at time of operation."2.65Tranexamic acid in alveolar sockets in the prevention of alveolitis sicca dolorosa. ( Gersel-Pedersen, N, 1979)
"Tranexamic acid appears to be an effective and well-tolerated agent for reduction of blood loss caused by local hyperfibrinolysis."2.64[Result of an antifibrinolytic treatment using tranexamic acid for the reduction of blood-loss during and after tonsillectomy]. ( Castelli, G; Vogt, E, 1977)
"Tranexamic acid (TXA) is an anti-fibrinolytic agent successfully preventing blood loss when using intravenously (IV) in total hip arthroplasty (THA) and total knee arthroplasty (TKA)."2.58Efficacy and safety of oral compared with intravenous tranexamic acid in reducing blood loss after primary total knee and hip arthroplasty: a meta-analysis. ( Gong, G; Han, N; Han, X; Liu, M, 2018)
"81) or and incidence of adverse effects such as infection (P = 0."2.53Efficiency and Safety of Intravenous Tranexamic Acid in Simultaneous Bilateral Total Knee Arthroplasty: A Systematic Review and Meta-analysis. ( Jiang, X; Ma, JX; Ma, XL, 2016)
"Tranexamic acid (TXA) is an antifibrinolytic drug used to reduce bleeding in mortality risk situations such as trauma."2.52Efficiency of tranexamic acid in perioperative blood loss in hip arthroplasty: a systematic literature review and meta-analysis. ( Díaz Quijano, DM; Pinzón-Florez, CE; Vélez Cañas, KM, 2015)
"Tranexamic acid (TXA) is an antifibrinolytic drug that has been shown to reduce blood loss following surgery."1.91Intravenous tranexamic acid is associated with an increased risk of pulmonary embolism following sarcoma resection. ( Foster, D; Garner, H; Goulding, K; Houdek, M; Sebro, R; Spaulding, AC; Stanborough, R; Wilke, B, 2023)
"Spinal surgery for scoliosis has been performed in selected patients with single ventricle physiology at a single institution without mortality for 25 years."1.62Surgical Correction of Scoliosis in Children with Severe Congenital Heart Disease and Palliated Single Ventricle Physiology. ( Cohen, LL; Emans, JB; Hedequist, DJ; Marshall, AC; Przybylski, R, 2021)
"Tranexamic acid (TXA) has proven to be safe in elective and traumatic femoral hemiarthroplasty; however, its use has not been investigated in oncologic patients."1.62Use of tranexamic acid is not associated with complications following bipolar hemiarthroplasty for metastatic disease. ( Houdek, MT; Owen, A; Rose, PS; Wellings, EP; Wyles, CC; Yuan, BJ, 2021)
"Tranexamic acid (TXA) has proven to be effective in reducing the blood loss associated with total knee arthroplasty (TKA) in patients with osteoarthritis."1.62Is there a role of tranexamic acid in rheumatoid arthritis with total knee arthroplasty? Findings from a multicenter prospective cohort study in China. ( Huang, Q; Huang, W; Lei, Y; Pei, F; Xie, J, 2021)
"PURPOSE OF THE STUDY Heterotopic ossification is a frequent and a well-known complication after elective primary total hip arthroplasty."1.62[Tranexamic Acid Reduces the Incidence of Heterotopic Ossifications after Elective Primary Total Hip Arthroplasty]. ( Debre, J; Dupal, J; Štěpán, Z, 2021)
"Tranexamic acid (TXA) is a medication that has been shown to decrease blood loss and risk of blood transfusion in total knee and total hip arthroplasty."1.56Effect of Tranexamic Acid on Wound Complications and Blood Loss in Total Ankle Arthroplasty. ( Falcon, S; Haleem, AM; Hollabaugh, K; Luick, L; Ringus, V; Steinmetz, RG; Stoner, J; Tkach, S, 2020)
"Tranexamic acid use in craniosynostosis surgery has increased dramatically since 2010."1.56Tranexamic Acid in Infantile Craniosynostosis Surgery: Friend or Foe? ( Bennett, WE; Cook, JA; Danforth, RM; Gerety, PA; Tholpady, SS, 2020)
"Tranexamic acid was administered in 54 (60."1.48Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. ( Bakkum-Gamez, JN; Borah, BJ; Cliby, WA; DeJong, SR; Dowdy, SC; Halverson, JW; Higgins, AA; Jankowski, CJ; Kor, DJ; Moriarty, JP; Otto, HA; Wallace, SK; Weaver, AL; Weinhold, MR, 2018)
"Tranexamic acid (TXA) is a commonly antifibrinolytic agent in cardiac surgeries with cardiopulmonary bypass (CPB), however, there is concern that it might increase incidence of stroke after cardiac surgery."1.46Intraoperative tranexamic acid is associated with postoperative stroke in patients undergoing cardiac surgery. ( Huo, YF; Sun, K; Sun, LH; Xing, XF; Yan, M; Yu, LN; Yu, YX; Zhang, FJ; Zhou, ZF, 2017)
"Of a total of 259 patients with craniosynostosis, 187 had nonsyndromic single-suture involvement; 69 of these patients (36."1.43Implementation of a Tranexamic Acid Protocol to Reduce Blood Loss During Cranial Vault Remodeling for Craniosynostosis. ( Diggs, B; Esmonde, N; Gries, H; Koh, J; Kuang, AA; Martin, DT; Schreiber, M; Selden, NR, 2016)
"Tranexamic acid (TXA) is a synthetic antifibrinolytic drug that competitively decreases the conversion of plasminogen to plasmin, thereby suppressing fibrinolysis."1.42Evaluating the safety and efficacy of tranexamic acid administration in pediatric cranial vault reconstruction. ( Claiborne, JR; Couture, DE; Crantford, JC; David, LR; Ririe, DG; Thompson, JT; Wood, BC, 2015)
"Tranexamic acid (TXA) is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin."1.42TXA in combat casualty care--does it adversely affect extremity reconstruction and flap thrombosis rates? ( Campbell, P; Fleming, M; Jessie, E; Lucas, DJ; Rodriguez, C; Sabino, J; Valerio, IL, 2015)
"Changes in the hemostasis system in choledocholithiasis, taking into account the obturation jaundice severity and possibility of the correction conduction, using miniinvasive operative interventions, were studied."1.40[Changes of the hemostasis system in patients with obturation jaundice caused by choledocholithiasis, and possibilities of their correction with the help of miniinvasive operative interventions]. ( Tkachenko, AI, 2014)
"The seizures were likely due to a total dose of 8 g of tranexamic acid (TXA) administered intraoperatively."1.39[A case of postoperative convulsive seizure following tranexamic acid infusion during aortic valve replacement]. ( Ichikawa, J; Kodaka, M; Komori, M; Kubota, S; Nakano, K; Nishiyama, K; Sato, N, 2013)
" Future tranexamic acid trials should assess the blood-conserving effect of tranexamic acid at a lower dosage and specifically monitor for seizure occurrence."1.38High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass. ( Dagenais, F; Dionne, S; Kalavrouziotis, D; Mohammadi, S; Voisine, P, 2012)
"Compared to the non-seizure group, seizure patients had an increased rate of postoperative neurological complications, defined as delirium and/or stroke (3."1.38Seizures following cardiac surgery: the impact of tranexamic acid and other risk factors. ( Ariano, RE; Grocott, HP; Jacobsohn, E; Leake, J; Manji, JS; Manji, RA; Menkis, AH, 2012)
"Postoperative seizures occurred significantly more frequently in TXA patients (7."1.37Seizures after open heart surgery: comparison of ε-aminocaproic acid and tranexamic acid. ( Breuer, T; Gertler, R; Knorr, J; Lange, R; Macguill, M; Martin, K; Tassani, P; Wiesner, G, 2011)
"All patients with seizures did not have permanent neurological abnormalities."1.36High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients. ( Burt, C; Chu, M; Falter, F; Granton, J; Murkin, JM; Young, B, 2010)
" Further confirmatory prospective studies evaluating the efficacy and safety profile of TXA are urgently needed to find a safe dosage for this antifibrinolytic drug."1.36Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis. ( Martiny, V; Rosenthal, C; Sander, M; Spies, CD; von Heymann, C; Wernecke, KD, 2010)
"The exact mechanism of TxA-induced seizures is thought to be via inhibition of gamma-aminobutyric acid receptors in neurons."1.36Tranexamic Acid in cardiac surgery and postoperative seizures: a case report series. ( Almeida, A; Bell, D; Marasco, S; Rowland, M, 2010)
" The protamine dose necessary to reverse heparin after extracorporeal circulation (ECC) was assessed in ten patients from individual heparin dose-response curves (HDR group)."1.27The value of activated coagulation time in monitoring heparin therapy during extracorporeal circulation. ( Hatteland, K; Ottesen, S; Stormorken, H, 1984)

Research

Studies (218)

TimeframeStudies, this research(%)All Research%
pre-199029 (13.30)18.7374
1990's18 (8.26)18.2507
2000's13 (5.96)29.6817
2010's105 (48.17)24.3611
2020's53 (24.31)2.80

Authors

AuthorsStudies
Petersen, W1
Bentzin, M1
Bierke, S1
Park, HU1
Häner, M1
Chang, MJ1
Shin, JY1
Yoon, C1
Kim, TW1
Chang, CB1
Kang, SB1
Peng, L1
Zeng, J2
Zeng, Y2
Wu, Y1
Yang, J2
Shen, B1
Wang, J3
Zhang, Z1
Li, J6
Huang, B1
Jiang, Z1
Pan, Y1
He, T1
Hu, Y1
Wang, L2
Moore, AD1
Smith, BR1
O'Leary, RJ1
Hoch, CP1
Gross, CE1
Scott, DJ1
Mei, J1
Kim, CH1
Hwang, J1
Lee, SJ1
Yoon, PW1
Yoon, KS1
Lech, P1
Michalik, M1
Waczyński, K1
Osowiecka, K1
Dowgiałło-Gornowicz, N1
Li, Y1
Huang, Y2
Zhang, H2
Ye, P1
Deng, P1
Chen, J3
Qi, X1
Feng, W1
Yang, X1
Chai, M1
Xia, L1
He, Z1
Wu, X1
Zhang, J2
de Paula, MVCT1
Ribeiro, BDC1
Melo, MM1
de Freitas, PVV1
Pahl, FH1
de Oliveira, MF1
Rotta, JM1
Foster, D1
Sebro, R1
Garner, H1
Stanborough, R1
Spaulding, AC2
Goulding, K1
Houdek, M1
Wilke, B1
Chang, YJ1
Lin, YH1
Wang, PL1
Lin, HC1
Zhao, M1
Geng, X1
Wang, C1
Zeng, L1
Tian, H1
Hulde, N2
Zittermann, A2
Deutsch, MA2
von Dossow, V2
Gummert, JF2
Koster, A2
Sukeik, M1
Alshryda, S1
Powell, J1
Haddad, FS1
King, L1
Randle, R1
Dare, W1
Bernaitis, N1
Bradley, KE1
Ryan, SP1
Penrose, CT1
Grant, SA1
Wellman, SS1
Attarian, DE1
Green, CL1
Risoli, T1
Bolognesi, MP1
Gerstein, NS1
Cushnyr, BW1
Petersen, TR1
Siegel, D1
Xu, Y1
Sun, S1
Feng, Q1
Zhang, G1
Dong, B1
Wang, X2
Guo, M1
Taunton, MJ1
Simon, RP1
Oromendia, C1
Sanso, LM1
Ramos, LG1
Rajwani, K1
Jules-Elysee, KM1
Tseng, A1
Sculco, TP1
Baaklini, LR1
McLawhorn, AS1
Pickard, AJ1
Qin, W1
Cross, JR1
Su, EP1
Fields, KG1
Mayman, DJ1
Chen, SH1
Chen, JY2
Wong, TH1
Buechel, F1
Wu, MH1
Hines, JT1
Petis, SM1
Amundson, AW1
Pagnano, MW3
Sierra, RJ1
Abdel, MP2
An, YZ1
Xu, MD1
An, YC1
Liu, H2
Zheng, M1
Jiang, DM1
Lloyd, TD1
Neal-Smith, G1
Fennelly, J1
Claireaux, H1
Bretherton, C1
Carr, AJ1
Murphy, M1
Kendrick, BJ1
Palmer, AJR1
Wan, Y1
Steinmetz, RG1
Luick, L1
Tkach, S1
Falcon, S1
Stoner, J1
Hollabaugh, K1
Ringus, V1
Haleem, AM1
Biboulet, P1
Motais, C1
Pencole, M1
Karam, O1
Dangelser, G1
Smilevitch, P1
Maissiat, G1
Capdevila, X1
Bringuier, S1
Weissler, JM1
Banuelos, J1
Jacobson, SR1
Manrique, OJ1
Nguyen, MT1
Harless, CA1
Tran, NV1
Martinez-Jorge, J1
Bai, T1
Liu, Y2
Wang, HY3
Yuan, MC1
Pei, FX2
Zhou, ZK2
Liao, R1
Yang, L1
Jia, X1
Kang, J1
Levent, A1
Köse, Ö1
Linke, P1
Gehrke, T1
Çıtak, M1
Kuint, R1
Levy, L1
Cohen Goichman, P1
Huszti, E1
Abu Rmeileh, A1
Shriki, O1
Abutbul, A1
Fridlender, ZG1
Berkman, N1
Ashkenazi, I1
Schermann, H1
Gold, A1
Gurel, R1
Chechik, O1
Warschawski, Y1
Schwarzkopf, R1
Snir, N1
Sun, C1
Zhang, X2
Chen, L2
Deng, J2
Ma, Q1
Cai, X1
Yang, H3
Danforth, RM1
Cook, JA1
Bennett, WE1
Tholpady, SS1
Gerety, PA1
Belk, JW1
McCarty, EC1
Houck, DA1
Dragoo, JL1
Savoie, FH1
Thon, SG1
Kang, BX1
Li, YL1
Xu, H2
Gao, CX1
Zhong, S1
Xie, J5
Sun, ST1
Xu, XR1
Zhao, C1
Ma, YH1
Zhai, WT1
Xiao, LB1
Hu, XX1
Owen, A1
Wellings, EP1
Wyles, CC1
Yuan, BJ1
Rose, PS1
Houdek, MT1
Lei, Y1
Huang, Q5
Huang, W2
Pei, F5
Cohen, LL1
Przybylski, R1
Marshall, AC1
Emans, JB1
Hedequist, DJ1
Shrestha, IK1
Ruan, TY1
Lin, L1
Tan, M1
Na, XQ1
Qu, QC1
Chen, JC1
Si, YY1
Tao, JP1
Reale, D1
Andriolo, L1
Gursoy, S1
Bozkurt, M1
Filardo, G1
Zaffagnini, S1
İpek, HD1
Bezgin, SÜ1
Çakabay, T1
Çelebi, Ş1
Choi, YJ1
Park, HJ1
Lee, HJ1
Lee, GY1
Kim, WS1
Batagello, CA1
Vicentini, FC1
Monga, M1
Miller, AW1
Marchini, GS1
Torricelli, FCM1
Danilovic, A1
Coelho, RF1
Srougi, M1
Nahas, WC1
Mazzucchi, E1
Burton, H1
Mossadegh, S1
McCarthy, R1
Varady, NH1
Chen, AF1
Drayer, NJ1
Ready, J1
Lozano-Calderon, SA1
Hayden, BL1
Debre, J1
Štěpán, Z1
Dupal, J1
Shi, H1
Zhou, ZM1
Xu, ZY1
Zhu, L1
Jiang, ZL1
Wu, XT1
Ma, J3
Lu, H1
Chen, X2
Wang, D2
Wang, Q3
Changjun, C1
Xin, Z1
Yue, L1
Chengcheng, Z1
Qiuru, W1
Qianhao, L1
Pengde, K1
Madden, A1
Hulme, P1
Porter, SB1
Duncan, CM1
Wilke, BK1
Wei, H1
Xiao, Q1
He, J1
Huang, T1
Xu, W1
Xian, S1
Xia, M1
Liu, X1
Liu, J2
Sun, G1
Mi, B1
Liu, G1
Zhou, W1
Lv, H1
Zha, K1
Wu, Q1
Ghavimi, MA1
Taheri Talesh, K1
Ghoreishizadeh, A1
Chavoshzadeh, MA1
Zarandi, A1
Zhou, ZF1
Zhang, FJ1
Huo, YF1
Yu, YX1
Yu, LN1
Sun, K1
Sun, LH1
Xing, XF1
Yan, M1
Mehdizadeh, M1
Ghassemi, A1
Khakzad, M1
Mir, M1
Nekoohesh, L1
Moghadamnia, A1
Bijani, A1
Mehrbakhsh, Z1
Ghanepur, H1
Baskaran, D1
Rahman, S1
Salmasi, Y1
Froghi, S1
Berber, O1
George, M1
Wang, Z1
Shen, X1
Hu, Q2
Shimauchi, T1
Yamaura, K1
Higashi, M1
Abe, K1
Yoshizumi, T1
Hoka, S1
Berkowitz, RL1
Queiroz, SIML1
Silvestre, VD1
Soares, RM1
Campos, GBP1
Germano, AR1
da Silva, JSP1
Yuan, X1
Dorweiler, MA1
Boin, MA1
Froehle, AW1
Lawless, MW1
May, JH1
Junejo, F1
Akhtar, MI1
Hamid, M1
Ahmed, SS1
Minai, F1
Amanullah, M1
Wallace, SK1
Halverson, JW1
Jankowski, CJ1
DeJong, SR1
Weaver, AL1
Weinhold, MR1
Borah, BJ1
Moriarty, JP1
Cliby, WA1
Kor, DJ1
Higgins, AA1
Otto, HA1
Dowdy, SC1
Bakkum-Gamez, JN1
Schiavone, A1
Bisaccia, M1
Inkov, I1
Rinonapoli, G1
Manni, M1
Rollo, G1
Meccariello, L1
Vicente, CI1
Ceccarini, P1
Ruggiero, C1
Caraffa, A1
Liu, Q1
Geng, P1
Shi, L1
Wang, P1
Zhu, Q1
Yu, C1
Xu, X1
Chen, Y1
Liu, C2
Lin, P1
Fraval, A1
Duncan, S1
Murray, T1
Duggan, J1
Tirosh, O1
Tran, P1
de Vasconcellos, SJA1
do Nascimento-Júnior, EM1
de Aguiar Menezes, MV1
Tavares Mendes, ML1
de Souza Dantas, R1
Martins-Filho, PRS1
Peck, J1
Kepecs, DM1
Mei, B1
Safir, OA1
Backstein, D1
Gross, AE1
Kuzyk, PR1
Lévy, Y1
Azar, M1
Tran, L1
Boileau, P1
Bronsard, N1
Trojani, C1
Dastrup, A1
Pottegård, A1
Hallas, J1
Overgaard, S1
Han, X1
Gong, G1
Han, N1
Liu, M2
Reichel, F1
Peter, C1
Ewerbeck, V1
Egermann, M1
Kim, DH1
Kim, S1
Kang, H1
Jin, HJ1
Hwang, SH1
McGuire, C1
Nurmsoo, S1
Samargandi, OA1
Bezuhly, M1
Sun, H2
Deng, L1
Chen, K1
Li, H1
Ning, X1
Erdogan, U1
Tanik, C1
Tanriverdi, O1
Gunaldi, O1
Yilmaz, I1
Arslanhan, A1
Ofluoglu, AE1
Sun, Q1
Zheng, C1
Jia, Y1
Luo, ZY1
Zeng, WN1
Zhang, Y2
He, F1
Chen, A1
Pi, B1
Jiang, W1
Shang, L1
Willems, A1
De Groote, F1
Dumoulin, M1
Fils, JF1
Van der Linden, P1
Spitler, CA1
Row, ER1
Gardner, WE1
Swafford, RE1
Hankins, MJ1
Nowotarski, PJ1
Kiner, DW1
Gulabi, D1
Yuce, Y1
Erkal, KH1
Saglam, N1
Camur, S1
Yang, R1
Wu, XD1
Xiao, PC1
Zhu, ZL1
Liu, JC1
Li, YJ1
Chiang, ER1
Chen, KH1
Wang, ST1
Ma, HL1
Chang, MC1
Liu, CL1
Chen, TH1
Chen, G2
Zhou, Z2
Cao, G1
Huang, Z1
Alexander, PG1
Lin, H1
Rutnin, S1
Pruettivorawongse, D1
Thadanipon, K1
Vachiramon, V1
Merriman, B1
Mayson, K1
Sawka, A1
Akagami, R1
Flexman, AM1
Chen, TT1
Wang, G1
Jiang, SL1
Li, LB1
Gao, CQ1
Ichikawa, J1
Kodaka, M1
Nishiyama, K1
Sato, N1
Kubota, S1
Nakano, K1
Komori, M1
Muñoz Gómez, M1
Páramo Fernández, JA1
Zhou, XD1
Tao, LJ1
Wu, LD1
Georgiadis, AG1
Muh, SJ1
Silverton, CD1
Weir, RM1
Laker, MW1
Chimento, GF1
Huff, T1
Ochsner, JL1
Meyer, M1
Brandner, L1
Babin, S1
Makhija, N1
Sarupria, A1
Kumar Choudhary, S1
Das, S1
Lakshmy, R1
Kiran, U1
Sjoblom, MD1
Busso, VO1
Linscott, LL1
Sadhasivam, S1
Sakallioğlu, Ö1
Polat, C1
Soylu, E1
Düzer, S1
Orhan, İ1
Akyiğit, A1
Irwin, A1
Khan, SK1
Jameson, SS1
Tate, RC1
Copeland, C1
Reed, MR1
Gertler, R2
Wiesner, G3
Tassani-Prell, P1
Martin, K3
Gruber, M1
Clerico, C1
Benatar, M1
Dumontier, C1
Schwameis, M1
Thaler, J1
Schober, A1
Schörgenhofer, C1
Kulinna-Cosentini, C1
Laggner, A1
Röggla, M1
Jilma, B1
Tkachenko, AI1
Crantford, JC1
Wood, BC1
Claiborne, JR1
Ririe, DG1
Couture, DE1
Thompson, JT1
David, LR1
Pinzón-Florez, CE1
Vélez Cañas, KM1
Díaz Quijano, DM1
Valerio, IL1
Campbell, P1
Sabino, J1
Lucas, DJ1
Jessie, E1
Rodriguez, C1
Fleming, M1
Ali Shah, MU1
Asghar, MI1
Siddiqi, R1
Chaudhri, MS1
Janjua, AM1
Iqbal, A1
Wei, Z1
Hong, SK1
Duan, Y1
Yin, HM1
Bagsby, DT1
Samujh, CA1
Vissing, JL1
Empson, JA1
Pomeroy, DL1
Malkani, AL1
Chin, PL1
Moo, IH1
Pang, HN1
Tay, DK1
Chia, SL1
Lo, NN1
Yeo, SJ1
Liu, KL1
Chen, IH1
Wen, SH1
Sargant, N1
Roy, A1
Simpson, S1
Chandrakumaran, K1
Alves, S1
Coakes, J1
Bell, J1
Knight, J1
Wilson, P1
Mohamed, F1
Cecil, T1
Moran, B1
Abolghasemian, M1
Huether, TW1
Soever, LJ1
Drexler, M1
MacDonald, MP1
Backstein, DJ1
Sun, X1
Dong, Q1
Zhang, YG1
Soroceanu, A1
Oren, JH1
Smith, JS1
Hostin, R1
Shaffrey, CI1
Mundis, GM1
Ames, CP1
Burton, DC1
Bess, S1
Gupta, MC1
Deviren, V1
Schwab, FJ1
Lafage, V1
Errico, TJ1
Akgül, T1
Büget, M1
Salduz, A1
Edipoğlu, İS1
Ekinci, M1
Küçükay, S1
Şen, C1
Coomber, R1
Porteous, M1
Hubble, MJW1
Parker, MJ1
Martin, DT1
Gries, H1
Esmonde, N1
Diggs, B1
Koh, J1
Selden, NR1
Schreiber, M1
Kuang, AA1
Jiang, X1
Ma, XL1
Ma, JX1
Myles, PS1
Smith, JA1
Forbes, A1
Silbert, B1
Jayarajah, M1
Painter, T1
Cooper, DJ1
Marasco, S2
McNeil, J1
Bussières, JS1
McGuinness, S1
Byrne, K1
Chan, MT1
Landoni, G1
Wallace, S1
Fígar, A1
Mc Loughlin, S1
Slullitel, PA1
Scordo, W1
Buttaro, MA1
Yu, SK1
Callum, J1
Alam, A1
Yue, C1
Lindvall, G1
Sartipy, U1
Ivert, T1
van der Linden, J1
Breuer, T2
Wilhelm, M1
Schreiber, C1
Hess, J1
Lange, R2
Tassani, P2
Nicolau-Raducu, R1
Subramaniam, K1
Marquez, J1
Wells, C1
Hilmi, I1
Sullivan, E1
Karkouti, K1
Wijeysundera, DN1
Yau, TM2
McCluskey, SA1
Tait, G1
Beattie, WS1
Murkin, JM1
Falter, F1
Granton, J1
Young, B1
Burt, C1
Chu, M1
Yadav, SP1
Sachdeva, A1
Bhat, S1
Katewa, S1
Nakaigawa, N1
Kamata, K1
Komatsu, R1
Ozaki, M1
Hewson, I1
Makhmalbaf, P1
Street, A1
McCarthy, P1
Walsh, M1
Sander, M1
Spies, CD1
Martiny, V1
Rosenthal, C1
Wernecke, KD1
von Heymann, C1
Bell, D1
Almeida, A1
Rowland, M1
Chevet, I1
Remérand, F1
Couvret, C1
Baud, A1
Pouplard, C1
Rosset, P1
Laffon, M1
Fusciardi, J1
Knorr, J1
Macguill, M1
Wahba, A2
Vonk, A1
Bidstrup, B1
Goldstone, AB1
Bronster, DJ1
Chikwe, J1
Muedra, V1
Delás, F1
Villalonga, V1
Gómez, M1
Sánchez, F1
Llopis, JE1
Lecker, I1
Orser, BA1
Mazer, CD2
Kalavrouziotis, D1
Voisine, P1
Mohammadi, S1
Dionne, S1
Dagenais, F1
Manji, RA1
Grocott, HP1
Leake, J1
Ariano, RE1
Manji, JS1
Menkis, AH1
Jacobsohn, E1
Brum, MR1
Miura, MS1
Castro, SF1
Machado, GM1
Lima, LH1
Lubianca Neto, JF1
Seo, JG1
Moon, YW1
Park, SH1
Kim, SM1
Ko, KR1
Hutton, B1
Joseph, L1
Fergusson, D1
Shapiro, S1
Tinmouth, A1
Watts, CD1
Pusateri, AE1
Weiskopf, RB1
Bebarta, V1
Butler, F1
Cestero, RF1
Chaudry, IH1
Deal, V1
Dorlac, WC1
Gerhardt, RT1
Given, MB1
Hansen, DR1
Hoots, WK1
Klein, HG1
Macdonald, VW1
Mattox, KL1
Michael, RA1
Mogford, J1
Montcalm-Smith, EA1
Niemeyer, DM1
Prusaczyk, WK1
Rappold, JF1
Rassmussen, T1
Rentas, F1
Ross, J1
Thompson, C1
Tucker, LD1
Pleym, H1
Stenseth, R1
Bjella, L1
Karevold, A1
Dale, O1
Vanek, T1
Jares, M1
Fajt, R1
Straka, Z1
Jirasek, K1
Kolesar, M1
Brucek, P1
Maly, M1
Abul-Azm, A1
Abdullah, KM1
Bremerich, DH1
Strametz, R1
Kirchner, R1
Moritz, A1
Zwissler, B1
Casati, V2
Galli, L1
D'Angelo, A1
Robertshaw, HJ1
Mouton, R1
Finch, D1
Davies, I1
Binks, A1
Zacharowski, K1
Sabato, AF1
Foti, A1
De Cosmo, G1
Bondoli, A1
Lundvall, F1
Nielsen, NC1
Grundsell, H1
Larsson, G1
Bekassy, Z1
Ottesen, S1
Stormorken, H1
Hatteland, K1
Hedelin, H1
Teger-Nilsson, AC1
Peterson, HI1
Pettersson, S1
Syrjänen, SM2
Syrjänen, KJ2
Pappalardo, G2
Caltabiano, M2
Bella, G2
Cicciù, D2
Miller, RA1
May, MW1
Hendry, WF1
Whitfield, HN1
Wickham, JE1
Smart, CJ1
Bewermeyer, H1
Szelies, B1
Lumenta, C1
Heiss, WD1
Cousin, MT1
Boughenou, F1
Madi-Jebara, S1
Massonnet-Vastel, S1
Benmosbah, L1
Fremes, SE1
Wong, BI1
Lee, E1
Mai, R1
Christakis, GT1
McLean, RF1
Goldman, BS1
Naylor, CD1
Coffey, A1
Pittmam, J1
Halbrook, H1
Fehrenbacher, J1
Beckman, D1
Hormuth, D1
Rousou, JA1
Engelman, RM1
Flack, JE1
Deaton, DW1
Owen, SG1
Ali, IM1
Landymore, RW1
Oertli, D1
Laffer, U1
Haberthuer, F1
Kreuter, U1
Harder, F1
Horrow, J1
Strong, MD2
Van Riper, DF1
Ramström, G1
Sindet-Pedersen, S1
Hall, G1
Blombäck, M1
Alander, U1
Lindoff, C1
Rybo, G1
Astedt, B1
Ovrum, E1
Am Holen, E1
Abdelnoor, M1
Oystese, R1
Ringdal, ML1
Katsaros, D1
Petricevic, M1
Snow, NJ1
Woodhall, DD1
Van Bergen, R1
Howes, JP1
Sharma, V1
Cohen, AT1
Castelli, R1
Cicardi, M1
Gardinali, M1
Zingale, LC1
Savi, C1
Munari, M1
Agostoni, A1
Dryden, PJ1
O'Connor, JP1
Jamieson, WR1
Reid, I1
Ansley, D1
Sadeghi, H1
Burr, LH1
Munro, AI1
Merrick, PM1
Hardy, JF1
Bélisle, S1
Dupont, C1
Harel, F1
Robitaille, D1
Roy, M1
Gagnon, L1
Benoni, G1
Lethagen, S1
Nilsson, P1
Fredin, H1
O'Brien, JG1
Battistini, B1
Zaharia, F1
Plante, GE1
Sirois, P1
Guzzon, D1
Oppizzi, M1
Bellotti, F1
Franco, A1
Gerli, C1
Cossolini, M1
Torri, G1
Calori, G1
Benussi, S1
Alfieri, O1
Ruel, MA1
Wang, F1
Bourke, ME1
Dupuis, JY1
Robblee, JA1
Keon, WJ1
Rubens, FD1
Obrant, KO1
Gersel-Pedersen, N1
Verstraete, M2
Tyberghein, J1
De Greef, Y1
Daems, L1
Van Hoof, A1
Fodstad, H1
Liliequist, B1
Schannong, M1
Thulin, CA1
Ehlers, N2
Bramsen, T2
Ward, MG1
Richards, B1
Hedlund, PO1
Jerndal, T1
Frisén, M1
Castelli, G1
Vogt, E1
Ali, G1
Ascanelli, L1
Pagliuso, G1
Prentice, CR1
Valsecchi, A1
Cappelletti, M1
Carson, S1
Weisel, RD1
Ivanov, J1
Sun, Z1
Yu, R1
Glynn, MF1
Teasdale, SJ1
Horrow, JC1
Hlavacek, J1
Collier, W1
Brodsky, I1
Goldman, SM1
Goel, IP1
Tsementzis, SA1
Hitchcock, ER1
Meyer, CH1
Nørrelykke Nissen, J1
Auvinen, O1
Baer, GA1
Nordback, I1
Saaristo, J1
Razis, PA1
Coulson, IH1
Gould, TR1
Findley, IL1

Clinical Trials (59)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective, Multicenter, Randomized, Parallel Groups Study Comparing the Safety and the Efficacy of the Administration of One Intra-articular Injection of 4.8 ml (HO-1) or Three Intra-articular Injections of 2.2 ml (HS-3) of Pandora Gel to One Intra-arti[NCT05978180]252 participants (Anticipated)Interventional2023-10-18Recruiting
Prospective, Multicenter, Open Study Evaluating the Short-term Safety of Use of Pandora Administered in the Form of 1 Intra-articular Injection of Happyone or 3 Intra-articular Injections of Happysoft in Patients Suffering From Gonarthrosis[NCT05414617]20 participants (Actual)Interventional2022-06-08Completed
Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage[NCT05554211]Phase 230 participants (Anticipated)Interventional2022-07-12Recruiting
Use of TRanEXamic Acid in Reduction Mammoplasty (TREX-ARM): a Double-blinded Randomized Controlled Trial[NCT04947514]Phase 498 participants (Actual)Interventional2021-10-29Completed
Effects of the Application of a New Pharmacological Protocol for Shoulder Arthroscopy in Beach Chair Position[NCT05397652]Phase 4104 participants (Actual)Interventional2021-05-24Completed
Impact of Tranexamic Acid Use in Transfusion Rate in Patients With Complex Kidney Stone Undergoing Percutaneous Nephrolithotomy: Randomised, Double-blind, Placebo Controlled Trial[NCT02966236]Phase 4192 participants (Anticipated)Interventional2016-06-30Recruiting
Tranexamic Acid's Effects in Patients Undergoing Laparoscopic Radical Prostatectomy: a Randomized, Double-blind, Placebo-controlled Trial[NCT05816668]Phase 3122 participants (Anticipated)Interventional2023-04-30Not yet recruiting
The Effects of the Timing of Tranexamic Acid Administration on Blood Loss in Hip Fractures.[NCT04488367]Early Phase 1120 participants (Anticipated)Interventional2020-07-06Recruiting
Efficacy of Tranexamic Acid (TXA) in Humerus ORIF[NCT05802238]Phase 2130 participants (Anticipated)Interventional2023-04-12Recruiting
Oral Tranexamic Acid vs. Oral Aminocaproic Acid to Reduce Blood Loss, Transfusion Index and Complications After Total Hip Replacement. A Prospective, Randomized, Double Blind Clinical Trial[NCT04187014]Phase 290 participants (Actual)Interventional2020-02-06Completed
Comparative Use of Tranexamic Acid Intravenous and Topical Application in the Treatment of Intertrochanteric Fractures With Proximate Femoral Nail[NCT04696224]90 participants (Anticipated)Interventional2020-12-18Recruiting
Tranexamic Acid in Rhinoplasty: Perioperative Bleeding, Edema and Ecchymosis[NCT05774717]Phase 160 participants (Anticipated)Interventional2023-04-01Recruiting
Effect of Tranexamic Acid on Postoperative Bleeding Following Sinus and Nasal Surgery[NCT04754230]Phase 440 participants (Actual)Interventional2021-06-17Completed
Efficacy of Tranexamic Acid in Femoral Shaft Fractures Osteosynthesis; A Double Blind Randomized Controlled Trial[NCT04803591]Phase 40 participants (Actual)Interventional2021-08-01Withdrawn (stopped due to Not approved by Ethics Commettee)
The Use of Tranexamic Acid in Irrigation Fluid to Improve Arthroscopic Visualization in Shoulder Surgery: A Randomized Controlled Trial[NCT04594408]Phase 4128 participants (Actual)Interventional2020-09-01Active, not recruiting
Single Centre Randomised Controlled Trial to Assess the Effect of the Addition of Twenty-four Hours of Oral Tranexamic Acid Post-operatively to a Single Intra-operative Intravenous Dose of Tranexamic Acid on Calculated Blood Loss Following Primary Hip and[NCT03690037]Phase 41,089 participants (Actual)Interventional2016-07-07Completed
Comparison of Combined Topical Tranexamic Acid With Floseal® With Intravenous Tranexamic Acid on Blood Loss in Total Knee Arthroplasty[NCT03328832]Phase 470 participants (Actual)Interventional2017-09-12Completed
Evaluating the Use of Tranexamic Acid (TXA) in Total Joint Arthroplasty[NCT03825939]Phase 452 participants (Actual)Interventional2015-04-21Terminated (stopped due to Lack of patient enrollment due to only one surgeon that was enrolling.)
Blood Loss Reduction After Total Knee Arthroplasty. A Comparison Between Topical Tranexamic Acid and Platelet Rich Plasma: Controlled Clinical Trial[NCT02650856]Phase 340 participants (Actual)Interventional2015-09-30Completed
Blood-saving Effect of Kaolin-based Hemostatic Gauze Combined With Intravenous Tranexamic Acid in Total Knee Arthroplasty[NCT05504577]Phase 4120 participants (Anticipated)Interventional2022-03-16Recruiting
Comparison of Topical and Infusion Tranexamic Acid on Blood Loss and Risk of Deep Vein Thrombosis After Total Knee Arthroplasty[NCT02453802]Phase 490 participants (Anticipated)Interventional2015-06-30Not yet recruiting
Comparison of Topical Tranexamic Acid and Floseal® on Blood Loss After Total Knee Arthroplasty in Patients With a Thromboembolic Risk[NCT02865174]Phase 490 participants (Anticipated)Interventional2016-09-30Not yet recruiting
The Effect of Intravenous E-Aminocaproic Acid (EACA) on Blood Loss and Transfusion Requirements After Bilateral Varus Rotational Osteotomy (VRO)[NCT02257580]Phase 428 participants (Actual)Interventional2015-04-01Completed
Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean Delivery: A Randomized Controlled Trial[NCT03364491]Phase 311,000 participants (Actual)Interventional2018-03-15Completed
The Effect of Local Tranexamic Acid on Post-operative Edema and Ecchymosis in Eyelid Surgery[NCT04951128]Phase 450 participants (Anticipated)Interventional2021-08-01Not yet recruiting
Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid in Patients at High Risk for Blood Transfusion After Spine Surgery[NCT03849443]Early Phase 1604 participants (Anticipated)Interventional2019-08-26Recruiting
Serial Use of Intravenous and Oral Tranexamic Acid in Primary Total Knee Arthroplasty Patients: A Randomized Controlled Study[NCT03109652]Phase 4144 participants (Anticipated)Interventional2017-07-10Recruiting
Prospective Randomized Study Comparing Topical Versus Intravenous Tranexamic Acid in Anterior Total Hip Arthroplasty[NCT03359525]Phase 4114 participants (Anticipated)Interventional2017-07-01Recruiting
Comparative Study For Role Of Different Prophylactic Doses Of Intravenous Tranexamic Acid In Reducing Blood Loss At Caesarean Section: A Randomised Controlled Trial[NCT02739815]Phase 4200 participants (Actual)Interventional2016-04-30Completed
Tranexamic Acid Versus Novel Uterine Cooling Technique in Reducing Blood Loss and Incidence of Postpartum Hemorrhage at Caesarean Section[NCT02780245]Phase 4100 participants (Actual)Interventional2016-06-30Completed
A Novel Technique Of Uterine Cooling During Repeated Cesarean Section For Reducing Blood Loss[NCT03793153]99 participants (Actual)Interventional2018-12-19Completed
Prevention of Postpartum Hemorrhage With Tranexamic Acid (TXA)[NCT03326596]Phase 41,000 participants (Anticipated)Interventional2018-04-20Recruiting
Tranexamic Acid to Prevent OpeRation in Chronic Subdural Hematoma. A Double-blind, Placebo-controlled, Multicentre, Randomized Controlled Clinical Trial[NCT03582293]Phase 3140 participants (Anticipated)Interventional2018-06-19Recruiting
DEPOSITION: Pilot Study Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery[NCT03376061]Phase 497 participants (Actual)Interventional2017-12-21Completed
Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery (DEPOSITION) Study[NCT03954314]Phase 33,242 participants (Actual)Interventional2019-09-17Terminated (stopped due to Upon the Data Safety Monitoring Board review of the interim analysis (75% of participants have finished their follow-up) on November 17, 2023, they made a recommendation to stop recruitment into the trial.)
Seizures After Cardiac Surgery -- A Prospective Study With Continuous EEG Monitoring[NCT01291992]100 participants (Actual)Observational2010-09-30Completed
Outcome Impact of Different Tranexamic Acid Regimen in Cardiac Surgery With Cardiopulmonary Bypass (the OPTIMAL Study)[NCT03782350]Phase 43,079 participants (Actual)Interventional2018-12-26Completed
Benefits on Post-operative Pain of Intravenous, Intraoperative, Tranexamic Acid Injection During Arthroscopic Shoulder Surgery.[NCT05302986]Phase 3220 participants (Anticipated)Interventional2023-02-24Recruiting
The Effect of Tranexamic Acid on Blood Loss and Transfusion Rates in Major Oncologic Surgery[NCT01980355]76 participants (Actual)Interventional2012-06-12Completed
Use of Tranexamic Acid for Bleeding Reduction in Adenotonsillectomy in Children[NCT01228136]Phase 495 participants (Actual)Interventional2010-01-31Completed
Efficacy of Low-dose Intra-articular Tranexamic Acid in Total Knee Replacement; A Prospective Triple-blinded Randomized Controlled Trial.[NCT01850394]152 participants (Actual)Interventional2010-01-31Completed
Efficacy and Safety of Erythropoietin And/Or Intravenous Iron Sucrose For Treatment of Anemia In Hip and Knee Arthroplasty: A Single-center Retrospective Study[NCT03917394]780 participants (Anticipated)Observational2019-04-24Recruiting
Role of Topical Tranexamic Acid in Total Hip Arthroplasty[NCT01866943]Phase 241 participants (Actual)Interventional2011-11-30Terminated
Topical Application Effect of Tranexamic Acid in Postoperative Bleeding and Blood Products Transfusion After Cardiac Surgery[NCT05708690]Phase 4132 participants (Actual)Interventional2022-10-01Completed
The Effect on Blood Loss of Topical and Intravenous Tranexamic Acid in Cardiac Surgery Patients: a Randomized Placebo-controlled Trial[NCT01895101]Phase 4750 participants (Actual)Interventional2013-10-31Completed
Topical Application of Tranexamic Acid to Reduce Post-operative Bleeding in Coronary Artery Bypass Surgery[NCT01519245]Phase 344 participants (Actual)Interventional2011-12-31Completed
Efficacy in Controlling Bleeding Post-coronary Bypass Surgery Using Combination of Local Application of Tranexamic Acid and Intravenous Tranexamic Compared to Intravenous Tranexamic Acid Alone. A Randomized Controlled Trial[NCT01600599]40 participants (Actual)Interventional2011-01-31Completed
Tranexamic Acid in Knee Joint Surgery - a Randomised Controlled Trial[NCT02278263]Phase 4150 participants (Actual)Interventional2014-12-31Completed
Cardiac Surgery : In Vivo Titration of Protamine[NCT00684450]138 participants (Actual)Interventional2008-06-30Completed
The Effect of Tranexamic Acid on Intraoperative and Post-Operative Bleeding in Functional Endoscopic Sinus Surgery: A Randomized, Prospective, Double-Blinded Study[NCT00671281]74 participants (Anticipated)Interventional2008-10-31Withdrawn (stopped due to Study was cancelled)
Does a Single Steroid Injection Reduce the Formation of Postmastectomy Seroma[NCT00307606]Phase 440 participants (Anticipated)Interventional2005-12-31Recruiting
Minimization of Bleeding Complications Through Utilization of Perioperative Tranexamic Acid in Breast Surgery: A Randomized Double-blinded Placebo-controlled Trial[NCT02615366]Phase 4800 participants (Anticipated)Interventional2016-02-29Not yet recruiting
Pilot RCT: Use of Tranexamic Acid (TXA) in Post Mastectomy Patients for Seroma and Hematoma Prevention[NCT03738527]Phase 4100 participants (Anticipated)Interventional2019-10-07Recruiting
Tranexamic Acid in Surgery of Advanced Ovarian Cancer - a Prospective Randomized Double Blind Placebo Controlled Study[NCT00740116]Phase 4100 participants (Actual)Interventional2008-03-31Completed
Role of Tranexamic Acid for Reducing Blood Loss in Patients Undergoing Major Gastro-intestinal Surgery[NCT01655641]Phase 2/Phase 3118 participants (Anticipated)Interventional2012-07-31Active, not recruiting
The Use of Tranexamic Acid to Reduce Blood Loss in Acetabular Surgery[NCT02684851]Phase 387 participants (Actual)Interventional2012-10-31Completed
Randomized Placebo Controlled Study Using Tranexamic Acid in Revision Total Hip Arthroplasty[NCT00375440]0 participants (Actual)Interventional2005-02-28Withdrawn (stopped due to Study halted prematurely as investigator left the institution.)
Evaluation of Tranexamic Acid Prior to Surgery in the Geriatric Hip Fracture Population for the Reduction of Post-Operative Blood Transfusion[NCT03923959]Phase 3400 participants (Anticipated)Interventional2020-02-01Active, not recruiting
Evaluation of the Safety and Efficacy of the Second Dose of Tranexamic Acid Administration of Trauma Patients: A Randomized, Double-blind Controlled Clinical Trial[NCT03846973]Phase 3220 participants (Actual)Interventional2018-12-02Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Breasts With Development of Hematoma

The number of breasts with clinically significant hematoma (collection of blood under the skin) requiring either conservative management or operative washout was determined. (NCT04947514)
Timeframe: Up to 30 days

Interventionbreasts (Number)
Treatment Side (Right or Left)2
Placebo Side (Right or Left)1

Number of Participants Requiring a Blood Transfusion

The number of participants requiring blood transfusion was based on the postoperative decline in hematocrit level (NCT04947514)
Timeframe: Up to 30 days

InterventionParticipants (Count of Participants)
Treatment Side (Right or Left)0
Placebo Side (Right or Left)0

Number of Participants With Deep Vein Thrombosis/Venous Thromboembolism

Incidence of clinically significant deep vein thrombosis or pulmonary embolism detected on imaging (ultrasound or CT scan) (NCT04947514)
Timeframe: Up to 30 days

InterventionParticipants (Count of Participants)
Treatment Side (Right or Left)0
Placebo Side (Right or Left)0

Bleeding VAS - POD1

Patient-reported Visual Analog Scale - Bleeding Score Day 1. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 1 (assessed within first 24 hours following surgery)

Interventionscore on a scale (Mean)
Normal Saline5.03
1,000mg IV Tranexamic Acid4.82

Bleeding VAS - POD2

Patient-reported Visual Analog Scale - Bleeding Score Day 2. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 2

Interventionscore on a scale (Mean)
Normal Saline4.47
1,000mg IV Tranexamic Acid3.89

Bleeding VAS - POD3

Patient-reported Visual Analog Scale - Bleeding Score Day 3. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 3

Interventionscore on a scale (Mean)
Normal Saline2.93
1,000mg IV Tranexamic Acid2.29

Bleeding VAS - POD4

Patient-reported Visual Analog Scale - Bleeding Score Day 4. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 4

Interventionscore on a scale (Mean)
Normal Saline2.12
1,000mg IV Tranexamic Acid1.44

Bleeding VAS - POD5

Patient-reported Visual Analog Scale - Bleeding Score Day 5. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 5

Interventionscore on a scale (Mean)
Normal Saline1.32
1,000mg IV Tranexamic Acid1.15

Bleeding VAS - POD6

Patient-reported Visual Analog Scale - Bleeding Score Day 6. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 6

Interventionscore on a scale (Mean)
Normal Saline1.36
1,000mg IV Tranexamic Acid0.76

Bleeding VAS - POD7

Patient-reported Visual Analog Scale - Bleeding Score Day 7. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 7

Interventionscore on a scale (Mean)
Normal Saline0.97
1,000mg IV Tranexamic Acid0.72

Frequency of Participant Follow-up

Number of patients in each arm requiring evaluation by the resident service for bleeding concerns expressed by the recovery nurse (in PACU), had any follow-up visit or phone call outside of regularly scheduled follow-up (NCT04754230)
Timeframe: Day of surgery through 1 week

,
InterventionParticipants (Count of Participants)
PACUFollow-up visitFollow-up phone call
1,000mg IV Tranexamic Acid012
Normal Saline002

Guaze Saturation VAS Though POD7

Patient-reported Visual Analog Scale - Guaze Saturation Score through Postoperative Day 7. Score range: 0 (not at all) to 10 (dripping blood). (NCT04754230)
Timeframe: Postoperative Day 2 through Postoperative Day 7

,
Interventionscore on a scale (Mean)
Postoperative day 2Postoperative day 3Postoperative day 4Postoperative day 5Postoperative day 6Postoperative day 7
1,000mg IV Tranexamic Acid4.562.090.760.400.290.28
Normal Saline5.163.031.741.110.990.80

Blood Transfusion Rate

We will record the event of blood transfusion, and calculate the incidence of transfusion (NCT03328832)
Timeframe: From the operation to the postoperative day 3 or 4

InterventionParticipants (Count of Participants)
Combined Topical TXA and Floseal1
Topical TXA Alone0

Incidence of Thrombosis Events

The composite of any venous thromoembolism events, ischemic heart attacks, cerebrovascular accidents (NCT03328832)
Timeframe: within 30 days of the operation

InterventionParticipants (Count of Participants)
Combined Topical TXA and Floseal0
Topical TXA Alone0

Total Blood Loss After Operation

Total blood loss was calculated according to Nadler et al., which used maximum postoperative reduction of the Hb level adjust for weight and height of the patient. The formula is as follows, Total blood loss = (Total blood volume x [change in Hb level / preoperative Hb level])x1000+volume transfused (NCT03328832)
Timeframe: From the operation to the postoperative day 3 or 4

Interventionml (Mean)
Combined Topical TXA and Floseal678
Topical TXA Alone733

Length of Hospital Stay

Measured in Days (NCT03825939)
Timeframe: At Hospital Discharge

InterventionDays (Mean)
Intravenous Tranexamic Acid3
Intravenous Placebo3
Intravenous Tranexamic Acid Followed by Intravenous Placebo3

Therapeutic Effect on Drainage Quantification

The blood quantification will be taken at 6am every day. (NCT02650856)
Timeframe: up to 2nd day post operative (24 and 48 hrs)

,
InterventionmL (Mean)
24 hours48 hours
Group 1 Tranexamic Acid246.4120.8
Group 2 Platelet Rich Plasma263.2140.2

Therapeutic Effect on Hematocrit Level

The blood test will be taken at 6am every day. Using the same laboratory parameters. (NCT02650856)
Timeframe: up to 3rd day post operative (Baseline, 24, 48 and 72hrs)

,
Interventionpercentage of Hematocrite (Mean)
Baseline24 hours48 hours72 hours
Group 1 Tranexamic Acid41.731.629.128.6
Group 2 Platelet Rich Plasma41.529.827.727.3

Therapeutic Effect on Hemoglobin Level

The blood test will be taken at 6am every day. Using the same laboratory parameters. (NCT02650856)
Timeframe: up to 3rd day post operative (Baseline, 24, 48 and 72hrs)

,
Interventiong/dL (Mean)
Baseline24 hours48 hours72 hours
Group 1 Tranexamic Acid13.610.39.59.3
Group 2 Platelet Rich Plasma13.69.99.29.1

Complications [VTE (Symptomatic of DVT or PE), Infection (Superficial, Deep), Hematoma, Seroma, Reoperation, and Death]

Incidence of VTE (symptomatic of DVT or PE), infection (superficial, deep), hematoma, seroma, reoperation, and death, measured in person-years ( x cases per 100,000 person years) (NCT02257580)
Timeframe: an expected average of 1 week (post-surgery), Follow-up at 6 weeks

Interventioncases per 100,000 person years (Number)
E-Aminocaproic Acid (EACA)0
Placebo0

Intraoperative Calculated Total Blood Loss

Determined by estimated blood volume, calculated using difference in preoperative and postoperative hemoglobin and applied to the Nadler equation for estimating blood volume while adjusting for transfused hemoglobin to produce a single metric of calculated intraoperative blood loss. (NCT02257580)
Timeframe: Intraoperative (3-6 hours)

InterventionmL (Mean)
E-Aminocaproic Acid (EACA)535.7
Placebo628.0

Intraoperative Cell Saver Utilization

Number of participants requiring 1 unit of intraoperative cell saver transfusion. Patients either received or did not receive intraoperative cell saver transfusion. The maximum number of intraoperative units transfused in this study was 1 unit. The count of participants in the data table refers to the number of patients who received this transfusion. (NCT02257580)
Timeframe: Intraoperative, 1 day

InterventionParticipants (Count of Participants)
E-Aminocaproic Acid (EACA)7
Placebo7

Length of Hospital Stay

postoperative day of discharge after surgery- day of intake. (NCT02257580)
Timeframe: Post-Surgery, an expected average of 1 week

Interventiondays (Mean)
E-Aminocaproic Acid (EACA)5.5
Placebo5.1

Post Operative Blood Loss

24 hour drain output (mL) (NCT02257580)
Timeframe: Post-Surgery, 24 hours

InterventionmL (Mean)
E-Aminocaproic Acid (EACA)72.5
Placebo103.3

Postoperative Allogeneic Blood Transfusion

The number of participants that required 1 unit of blood transfused post-operatively. Patients received blood if necessary post operatively, and the maximum number of units a patient received was 1. The count of participants refers to the number of patients who received this transfusion unit. (NCT02257580)
Timeframe: Post-Surgery, an expected average of 1 week

InterventionParticipants (Count of Participants)
E-Aminocaproic Acid (EACA)4
Placebo3

Change in Hemoglobin

[Key secondary outcome] Change in hemoglobin from the most recent measured before delivery to lowest measured in the 48 hours after delivery (NCT03364491)
Timeframe: from 4 weeks before delivery to 48 hours postpartum

Interventiongrams per deciliter (Mean)
Tranexamic Acid-1.8
Placebo-1.9

Length of Stay

Mother's length of stay from delivery to discharge (NCT03364491)
Timeframe: Until hospital discharge, an average of 3 days

Interventiondays (Median)
Tranexamic Acid3
Placebo3

Number of Mothers Who Died or Had Thromboembolic Events (Venous or Arterial), Ischemic Stroke, Myocardial Infarction, New-onset Seizure Activity, or Were Admitted to the Intensive Care Unit for More Than 24 Hours

(NCT03364491)
Timeframe: within 6 weeks postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid35
Placebo32

Number of Participants Who Received Open Label TXA or Other Antifibrinolytic

This is the number of mothers who were treated with any amount of open-label TXA (not blinded study drug) or another antifibrinolytic (eg., Amicar) (NCT03364491)
Timeframe: within 7 days postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid108
Placebo109

Number of Participants Who Received Surgical or Radiologic Interventions to Control Bleeding and Related Complications

This is the number of mothers who required any of the following types of surgical procedures to control bleeding: laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid233
Placebo231

Number of Participants Who Received Treatments and Interventions in Response to Bleeding and Related Complications

[Key secondary outcome] This is the number of mothers who received treatments and interventions to control bleeding such as: uterotonics such as prostaglandins or methergine, but excluding oxytocin; open label TXA or other antifibrinolytics; transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets or administration of any factor concentrates; laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid892
Placebo986

Number of Participants Who Were Transfused With 4 or More Units of Packed Red Blood Cells

Participants were categorized according to the amount of packed red blood cells or whole blood transfused, either as 0 to 3 units, or 4 or more units (NCT03364491)
Timeframe: within 7 days postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid20
Placebo19

Number of Participants Who Were Transfused With Other Blood Products

This is the number of mothers who received during the first 7 days after delivery a transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets, or received any factor concentrates (NCT03364491)
Timeframe: within 7 days postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid29
Placebo31

Number of Participants Who Were Treated With Uterotonics Other Than Oxytocin

This is the number of mothers who were treated with uterotonics such as prostaglandins or methergine, but excluding oxytocin, from delivery through 48 hours after delivery. (NCT03364491)
Timeframe: within 48 hours postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid649
Placebo732

Number of Participants With a Thromboembolic Event (Venous or Arterial), Ischemic Stroke, or Myocardial Infarction

[Key secondary outcome] This is the number of mothers who experienced a thromboembolic event, ischemic stroke, or myocardial infarction during the 6 weeks after delivery. (NCT03364491)
Timeframe: within 6 weeks postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid12
Placebo13

Number of Participants With Estimated Blood Loss Greater Than 1 Liter During Delivery

[Major secondary outcome] The surgeon or anesthesiologist estimated the blood loss during the delivery in milliliters, which was recorded in the anesthesia record and/or operative report (NCT03364491)
Timeframe: From skin incision to transfer from operating room, average of 1 hour

InterventionParticipants (Count of Participants)
Tranexamic Acid339
Placebo368

Number of Participants With Maternal Death or Transfusion of Packed Red Blood Cells

Participants were monitored from delivery until hospital discharge or 7 days after delivery (postpartum), whichever is sooner. This is the number of mothers who died for any reason, or had a blood transfusion of 1 or more units (of packed red blood cells, including whole blood or cell saver). (NCT03364491)
Timeframe: by hospital discharge or by 7 days postpartum, whichever is sooner

InterventionParticipants (Count of Participants)
Tranexamic Acid201
Placebo233

Number of Participants With Postpartum Infectious Complications

[Key Secondary Outcome] This is the number of mothers who experienced any of the following infectious complications in the 6 weeks after delivery: endometritis, surgical site infection, pelvic abscess (NCT03364491)
Timeframe: within 6 weeks postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid162
Placebo125

Number of Participants With Seizure Activity That Was Not Seen Prior to Study Enrollment

This is the number of mothers who experienced seizure activity, confirmed by central review, whose onset is after enrollment (NCT03364491)
Timeframe: within 6 weeks postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid2
Placebo0

Mean Concentration of TxA in Plasma Collected From Participants

Plasma TxA concentrations measured from blood samples taken upon arrival in the ICU (NCT03376061)
Timeframe: on arrival in ICU within 3 hours

Interventionmicrogram per milliliter per kilogram (Mean)
Topical TxA (Intervention)0.58
Intravenous TxA (Control)1.10

Median Number of Hours Participants Spent in ICU

Number of hours participants spent in the intensive care unit (ICU) (NCT03376061)
Timeframe: Number of hours spent in ICU from arrival to exit (collected at the Post-Operative Visit).

Interventionhours (Median)
Topical TxA (Intervention)23
Intravenous TxA (Control)26

Median Volume of Mediastinal Fluid Collected From Participants

Cumulative volume (mL) of fluid collected from mediastinal drainage tubes 24 hours after the surgical procedure (NCT03376061)
Timeframe: Fluid collected in the first 24 hours after the surgical procedure

InterventionmL (Median)
Topical TxA (Intervention)500
Intravenous TxA (Control)540

Number of Participants With Mortality

The occurrence of death due to any cause (NCT03376061)
Timeframe: Patients will be followed post-operatively until hospital discharge

InterventionParticipants (Count of Participants)
Topical TxA (Intervention)1
Intravenous TxA (Control)1

Number of Participants With RBC Transfusion

Patients requiring a red blood cell transfusion (NCT03376061)
Timeframe: Intra-operative and post-operative RBC transfusions

InterventionParticipants (Count of Participants)
Topical TxA (Intervention)19
Intravenous TxA (Control)23

Number of Participants With Re-operation for Bleeding or Tamponade

Occurrence of re-operation for the purpose of bleeding or cardiac tamponade (NCT03376061)
Timeframe: Patients will be followed post-operatively until hospital discharge

InterventionParticipants (Count of Participants)
Topical TxA (Intervention)0
Intravenous TxA (Control)1

Number of Participants With Seizures

Patients experiencing a post-operative seizure (NCT03376061)
Timeframe: Patients will be followed post-operatively until hospital discharge

InterventionParticipants (Count of Participants)
Topical TxA (Intervention)0
Intravenous TxA (Control)1

Estimated Blood Loss

Surgical blood loss estimation (NCT01980355)
Timeframe: From time of surgery to 90 days post hospital discharge

InterventionmL (Median)
Tranexamic Acid450
Placebo365

Number of Participants Who Required Transfusion

To determine the impact of perioperative administration of tranexamic acid on blood loss and transfusion rates in major oncologic surgery (NCT01980355)
Timeframe: From time of surgery to 90 days post hospital discharge

InterventionParticipants (Count of Participants)
Tranexamic Acid8
Placebo5

Number of Patients Required Blood Transfusion

(NCT01850394)
Timeframe: postoperative period (5 days after surgery)

Interventionparticipants (Number)
Control Group10
TXA-250 Group6
TXA-500 Group0

Total Hemoglobin Loss

Total hemoglobin loos measured by difference between hemoglobin preoperatively and the fourth postoperative day (NCT01850394)
Timeframe: 5 days after surgery

Interventiong/dL (Mean)
Control Group2.9
TXA-250 Group2.2
TXA-500 Group2.2

Knee Function Scores

"Knee function score was measured with 2 methods, and were evaluated preoperatively and then postoperatively at 3-month, 6-month, and 1-year period.~Knee Society Knee Score using for rating knee function measurement and subdivided into two parts; knee score and function score 1.1. Knee score : calculated from pain, presence of deformity, total range of flexion, alignment, and stability. Total score is 100 (0-100), more score means better.~1.2. Function score : calculated from patient's ability to walk and climb stairs. The score ranges from 0-100, more score means better.~Western Ontario and McMaster Universities Arthritis Index or WOMAC score : a widely used, standardized questionnaires for evaluating the condition of patients with knee osteoarthritis, including pain (score = 0-20), stiffness (0-8), and functional limitation (0-68). Total score ranges from 0-68, lower score means better." (NCT01850394)
Timeframe: 1 year after surgery

,,
Interventionunits on a scale (Mean)
Knee Society Knee score at 1 yearWOMAC score at 1 year
Control Group148.915.5
TXA-250 Group151.215.1
TXA-500 Group150.914.5

Number of Patients Having Postoperative Complications

"Postoperative complications were measured as an incidence of the following complications;~wound hematoma~surgical site infection~systemic infection~deep vein thrombosis~pulmonary embolism~knee stiffness requiring manipulation~medical complication such as myocardial infarction, congestive hear failure" (NCT01850394)
Timeframe: postoperative 1-year period

,,
Interventionparticipants (Number)
Re-clamp incidenceRe-dressing incidenceVenous thromboembolic complicationCongestive heart failure
Control Group6340
TXA-250 Group1011
TXA-500 Group0020

Perioperative Blood Loss

"Drainage blood loss measured by accumulating total drainage volume postoperatively~Calculated total blood loss measured by using specific formula and difference between hematocrit preoperatively and the fourth postoperative day" (NCT01850394)
Timeframe: 5 days after surgery

,,
Interventionml (Median)
Drainage blood lossCalculated total blood loss
Control Group546.9329.2
TXA-250 Group475.0239.7
TXA-500 Group430.2217.2

Estimated Blood Loss

Estimated Blood Loss defined as Pre Op Hgb mins the Post Op Day two Hgb. (NCT01866943)
Timeframe: Pre Op, Post Op Day 2

InterventionHemoglobin (grams/deciliter) (Mean)
Baseline Population2.93

Harris Hip Scores

Standardized questionnaire that measures clinical function related to the hip. Total potential range is from 4.0 - 96.0. A higher score indicates a more favorable clinical outcome. (NCT01866943)
Timeframe: 2 week

Interventionunits on a scale (Mean)
All Study Participants65.76

Harris Hip Scores

Standardized questionnaire that measures clinical function related to the hip. Total potential range is from 4.0 - 96.0. A higher score indicates a more favorable clinical outcome. (NCT01866943)
Timeframe: 6 week

Interventionunits on a scale (Mean)
All Study Participants81.77

Harris Hip Scores

Standardized questionnaire that measures clinical function related to the hip. Total potential range is from 4.0 - 96.0. A higher score indicates a more favorable clinical outcome. (NCT01866943)
Timeframe: Preoperative

Interventionunits on a scale (Mean)
All Study Participants58.34

Mid Thigh Circumference

Measurement of the thigh at the half way point between the prominence of the greater trochanter and the lateral epicondyle of the femur. No data recorded at 2 weeks or 6 weeks for this study population. (NCT01866943)
Timeframe: Pre Op

Interventioncentimeters (Mean)
Baseline Population52.99

Number of Participants Requiring Surgical Re-exploration

the secondary objective of this study is to determine whether pericardial lavage with saline gives an improvement in haemostasis, compared with no pericardial lavage, resulting in a reduction of surgical re-explorations and post-operative 12-hour blood loss. The choice for a surgical re-exploration will be decided according to the ICU protocol. (NCT01895101)
Timeframe: participants will be followed for the duration of ICU stay, an expected average of 2 days

Interventionparticipants (Number)
Pericardial Lavage With 200 ml Normothermic Saline Solution10
No Pericardial Lavage9
2 gr Tranexamic Acid Diluted in 200 ml Normothermic Saline12

Postoperative Blood Loss

The primary study parameter is 12 hours postoperative blood loss and is assessed by postoperative chest tube production. Postoperative chest tube production 12 hours after surgical procedure (NCT01895101)
Timeframe: 12 hours postoperative

Interventionml (Median)
Pericardial Lavage With 200 ml Normothermic Saline Solution290
No Pericardial Lavage300
2 gr Tranexamic Acid Diluted in 200 ml Normothermic Saline290

Total Red Blood Cell Transfusions (Cumulative of Pre, Peri and Postoperative Period)

The amount of red blood cell transfusions the patient receive pre, peri and postoperatively during their stay in the hospital. (NCT01895101)
Timeframe: participants will be followed for the duration of ICU stay, an expected average of 2 days/ And participants will be followed for the duration of hospital stay, an expected average of 3 weeks

InterventionIU (Mean)
Pericardial Lavage With 200 ml Normothermic Saline Solution0.7
No Pericardial Lavage1.1
2 gr Tranexamic Acid Diluted in 200 ml Normothermic Saline0.7

Number of Units of Packed Red Blood Cells (PRBC) Transfused Following Coronary Artery Bypass Graft Surgery

Research participants were to receive a blood transfusion in the Intensive Care Unit (ICU) post-operatively if hemoglobin reached a nadir of 80g/L, or at the discretion of the intensivist or cardiac surgeon according to patient clinical status. Transfusion was quantified based on the number of units of PRBC received. (1 unit = 1 bag of blood, as prepared by Canadian Blood Services). Clinical status of research participants was followed throughout their duration in the ICU only. Participation in this study ended upon transfer out of the ICU, to the Cardiology Ward. (NCT01519245)
Timeframe: From ICU admission to transfer to the Cardiology Ward (placebo group = 24.4 hours; trial group = 24.7 hours)

InterventionUnit(s) of PRBC (Number)
Trial Drug0
Placebo0

Total Volume of Blood Loss From Mediastinal Chest Tubes at Time of Removal (Assuming the Total Volume of Loss is Blood).

According to standard practice, research participants were be transferred to the intensive care unit (ICU) for post-operative monitoring. Measurement of chest tube output began immediately on arrival to the ICU. Hourly measurements were recorded. Data collection ended upon chest tube removal, or return to the operating room for exploratory surgery due to massive blood loss. As per ICU protocol, chest tubes were be removed when blood loss was recorded to be less than 200mL after six consecutive hours. (NCT01519245)
Timeframe: From ICU admission post-operatively to mediastinal chest tube removal (placebo group = 20.6 hours; trial group = 19.8 hours)

InterventionmL (Mean)
Trial Drug632
Placebo789

Volume of Blood Loss After 12 Hours

Volume of chest tube loss at 12 hours (assuming the total volume of loss is blood). (NCT01519245)
Timeframe: 12 hours following admission to the Intensive Care Unit

InterventionmL (Mean)
Trial Drug464
Placebo570

Volume of Blood Loss at 6 Hours

Volume of chest tube loss at 6 hours (assuming the total volume of loss is blood). (NCT01519245)
Timeframe: 6 hours following admission to the Intensive Care Unit

InterventionmL (Mean)
Trial Drug342
Placebo417

Blood Loss

"The loss of haemoglobin (Hb) was then estimated according to the formula:~Hb(loss) = Blood volume (BV) x (Hbi-Hbe) x 0.001+Hbt~where Hb (loss) (g) is the amount of Hb lost, Hbi (g/L) the Hb concentration before surgery, Hbe (g/L) is the Hbe concentration on the third day after surgery, and Hbt (g) is the total amount of allogeneic Hb transfused. A unit of banked blood is considered to contain a minimum of 40g Hb (Blood component data sheet, New Zealand Blood Services [NZBS]). All units of blood are processed and stored in a nationally standardised manner. The blood loss (ml) was related to the patient's preoperative Hb value (g/L):~Blood loss =1000 x Hb(loss) /Hbi" (NCT02278263)
Timeframe: Post operative day 3

Interventionmls (Mean)
Control1090
Intraarticular716
Systemic746

Length of Stay (LOS)

Day of surgery is counted as Day 0. (NCT02278263)
Timeframe: Average length of stay is expected to be 3 to 5 days

Interventiondays (Median)
Control4
Topical4
Systemic4

Number of Participants Receiving Allogenic Blood Transfusion

"Those patients receiving blood products. Standardised protocol is as follows:~The criterion for transfusion of blood products will be a haemoglobin < 80g/L or a haemoglobin <100g/L in a patient with ischaemic heart disease or with significant symptomatology" (NCT02278263)
Timeframe: Participants will be followed for the duration of their hospital stay expected to be an average of 3-5 days

InterventionParticipants (Count of Participants)
Control2
Topical1
Systemic0

Perioperative Fluid Administration

Intravenous fluid (excluding blood transfusion) given during and first 24 hours after surgery (NCT02278263)
Timeframe: Day 1

Interventionmls (Mean)
Control1765
Topical1613
Systemic1807

Number of Participants Experiencing Symptomatic Venothromboembolic (VTE) Disease

Rates of deep vein thrombosis (DVT) and pulmonary embolus (PE) in each group recorded as a percentage (NCT02278263)
Timeframe: Postoperatively within 30 days after surgery

,,
InterventionParticipants (Count of Participants)
DVTPE
Control00
Systemic01
Topical02

Range of Active Flexion

Range of motion measured in degrees on postoperative days 1-3 (NCT02278263)
Timeframe: Days 1-3

,,
Interventiondegrees (Mean)
Day 1Day 2Day 3
Control577175
Systemic587278
Topical657582

Range of Passive Flexion

Range of motion measured in degrees for postoperative days 1 to 3 (NCT02278263)
Timeframe: Days 1-3

,,
Interventiondegrees (Mean)
Day 1Day 2Day 3
Control657682
Systemic688087
Topical748187

Median Number of Transfused Units of Red Blood Cells (RBC)

Median number of red blood cells transfused among those who received RBC transfusions (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks

Interventionunits (Median)
The Placebo Group2
The Tranexamic Acid Group2

Number of Patients Receiving Blood Transfusions

Total number of RBC-transfused women in each group (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks

Interventionparticipants (Number)
Tranexamic Group15
Placebo Group22

Number of Patients With Clinically or Radiologically Verified Thromboembolic Events Within 5 Weeks Postoperatively

Thromboembolic events including arterial thrombosis, muscle vein thrombosis, superficial and deep venous thrombosis. (NCT00740116)
Timeframe: From time of operation to 5 weeks postoperatively.

InterventionParticipants (Count of Participants)
Tranexamic Group2
Placebo Group5

Number of Units of Red Blood Cells (RBC) Transfused

Total number of red blood cells (RBC) transfused across all participants (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks

Interventionunits (Number)
Tranexamic Group38
Placebo Group53

Perioperative Bleeding Volume

Estimation of total blood loss was based on the estimation of the Hb balance method (Brecher, et al.1997) with the assumption that the body blood volume was normalised on the fifth postoperative day. The haemoglobin level was assessed preoperatively and on the fifth postoperative day. The predicted blood volume (PBV, l) was calculated according to the method described by Nadler et al. (1962), using body weight and height. The extravasation of haemoglobin was calculated taking into account allogenic transfused haemoglobin. Total blood loss perioperatively was related to the patient's preoperative haemoglobin value. Blood loss due to haematomas or a reoperation within the first five days after surgery was also considered. (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks

Interventionmilliliter (Median)
Tranexamic Group520
Placebo Group730

Allogenic Blood Transfusion Rates

Number of participant received allogenic blood transfusions. (NCT02684851)
Timeframe: post-operative

InterventionParticipants (Count of Participants)
Tranexamic21
Placebo13

Estimate Blood Loss

To measure average estimate perioperative blood loss (NCT02684851)
Timeframe: perioperative

InterventionmL (Mean)
Tranexamic727.6
Placebo560.1

Number of Participants With a Thromboembolic Event

Do patients undergoing acetabular ORIF who receive tranexamic acid have a higher risk for thromboembolic events than patients who receive placebo? (NCT02684851)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tranexamic1
Placebo0

Units of Packed Red Blood Cells Transfused

Average units packed red blood cells transfused among participants (NCT02684851)
Timeframe: perioperative

InterventionUnits of packed red blood cells (Mean)
Tranexamic2.65
Placebo2.36

Reviews

34 reviews available for tranexamic acid and Complication, Postoperative

ArticleYear
The effect of tranexamic acid in open reduction and internal fixation of pelvic and acetabular fracture: A systematic review and meta-analysis.
    Medicine, 2022, Jul-22, Volume: 101, Issue:29

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Fracture Fixation, Internal; Hip Fractures; Humans; P

2022
The effect of tranexamic acid on wound complications in primary total Hip Arthroplasty: A meta-analysis.
    The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland, 2020, Volume: 18, Issue:1

    Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Humans; Postoperative Complications; Pulmon

2020
The efficiency and safety of oral tranexamic acid in total hip arthroplasty: A meta-analysis.
    Medicine, 2019, Volume: 98, Issue:46

    Topics: Administration, Oral; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical;

2019
Comparison of oral versus intravenous tranexamic acid in total knee and hip arthroplasty: A GRADE analysis and meta-analysis.
    Medicine, 2020, Oct-30, Volume: 99, Issue:44

    Topics: Administration, Oral; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replace

2020
Tranexamic Acid Use in Knee and Shoulder Arthroscopy Leads to Improved Outcomes and Fewer Hemarthrosis-Related Complications: A Systematic Review of Level I and II Studies.
    Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association, 2021, Volume: 37, Issue:4

    Topics: Adult; Anterior Cruciate Ligament Reconstruction; Arthroscopy; Hemarthrosis; Humans; Knee; Lysholm K

2021
The efficacy and safety of high-dose tranexamic acid in adolescent idiopathic scoliosis: a meta-analysis.
    Journal of orthopaedic surgery and research, 2021, Jan-14, Volume: 16, Issue:1

    Topics: Adolescent; Blood Loss, Surgical; Female; Humans; Infusions, Intravenous; Intraoperative Complicatio

2021
Complications of Tranexamic Acid in Orthopedic Lower Limb Surgery: A Meta-Analysis of Randomized Controlled Trials.
    BioMed research international, 2021, Volume: 2021

    Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Humans; Lo

2021
The efficacy and safety of tranexamic acid in high tibial osteotomy: a systematic review and meta-analysis.
    Journal of orthopaedic surgery and research, 2021, Jun-11, Volume: 16, Issue:1

    Topics: Blood Loss, Surgical; Female; Hemoglobins; Humans; Male; Osteotomy; Postoperative Complications; Saf

2021
A comparison of combined intravenous and topical administration of tranexamic acid with intravenous tranexamic acid alone for blood loss reduction after total hip arthroplasty: A meta-analysis.
    International journal of surgery (London, England), 2017, Volume: 41

    Topics: Administration, Cutaneous; Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Repla

2017
Intra-articular versus intravenous tranexamic acid application in total knee arthroplasty: a meta-analysis of randomized controlled trials.
    Archives of orthopaedic and trauma surgery, 2017, Volume: 137, Issue:7

    Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S

2017
Effect of tranexamic acid use on blood loss and thromboembolic risk in hip fracture surgery: systematic review and meta-analysis.
    Hip international : the journal of clinical and experimental research on hip pathology and therapy, 2018, Volume: 28, Issue:1

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hemoglobins; Hip Fractures; Humans

2018
Effect of tranexamic acid use on blood loss and thromboembolic risk in hip fracture surgery: systematic review and meta-analysis.
    Hip international : the journal of clinical and experimental research on hip pathology and therapy, 2018, Volume: 28, Issue:1

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hemoglobins; Hip Fractures; Humans

2018
Effect of tranexamic acid use on blood loss and thromboembolic risk in hip fracture surgery: systematic review and meta-analysis.
    Hip international : the journal of clinical and experimental research on hip pathology and therapy, 2018, Volume: 28, Issue:1

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hemoglobins; Hip Fractures; Humans

2018
Effect of tranexamic acid use on blood loss and thromboembolic risk in hip fracture surgery: systematic review and meta-analysis.
    Hip international : the journal of clinical and experimental research on hip pathology and therapy, 2018, Volume: 28, Issue:1

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hemoglobins; Hip Fractures; Humans

2018
The efficacy of combined intra-articular and intravenous tranexamic acid for blood loss in primary total knee arthroplasty: A meta-analysis.
    Medicine, 2017, Volume: 96, Issue:42

    Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L

2017
Tranexamic acid versus aminocaproic acid for blood management after total knee and total hip arthroplasty: A systematic review and meta-analysis.
    International journal of surgery (London, England), 2018, Volume: 54, Issue:Pt A

    Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Repl

2018
Efficacy and Safety of Tranexamic Acid for Blood Salvage in Intertrochanteric Fracture Surgery: A Meta-Analysis.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2018, Volume: 24, Issue:8

    Topics: Hip Fractures; Humans; Operative Blood Salvage; Postoperative Complications; Thromboembolism; Tranex

2018
Preoperative Tranexamic Acid for Treatment of Bleeding, Edema, and Ecchymosis in Patients Undergoing Rhinoplasty: A Systematic Review and Meta-analysis.
    JAMA otolaryngology-- head & neck surgery, 2018, 09-01, Volume: 144, Issue:9

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Drug Administration Schedule; Ecchymosis; Edema; Eyel

2018
Efficacy and safety of oral compared with intravenous tranexamic acid in reducing blood loss after primary total knee and hip arthroplasty: a meta-analysis.
    BMC musculoskeletal disorders, 2018, Dec-03, Volume: 19, Issue:1

    Topics: Administration, Intravenous; Administration, Oral; Antifibrinolytic Agents; Arthroplasty, Replacemen

2018
Efficacy of tranexamic acid on operative bleeding in endoscopic sinus surgery: A meta-analysis and systematic review.
    The Laryngoscope, 2019, Volume: 129, Issue:4

    Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Endoscopy; Female; Humans; Incidence; Male; Mi

2019
Role of Tranexamic Acid in Reducing Intraoperative Blood Loss and Postoperative Edema and Ecchymosis in Primary Elective Rhinoplasty: A Systematic Review and Meta-analysis.
    JAMA facial plastic surgery, 2019, May-01, Volume: 21, Issue:3

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Ecchymosis; Edema; Humans; Postoperative Complication

2019
Comparison of intravenous, topical or combined routes of tranexamic acid administration in patients undergoing total knee and hip arthroplasty: a meta-analysis of randomised controlled trials.
    BMJ open, 2019, 01-28, Volume: 9, Issue:1

    Topics: Administration, Intravenous; Administration, Topical; Anemia; Antifibrinolytic Agents; Arthroplasty,

2019
Does Tranexamic Acid Improve Bleeding, Transfusion, and Hemoglobin Level in Patients Undergoing Multilevel Spine Surgery? A Systematic Review and Meta-Analysis.
    World neurosurgery, 2019, Volume: 127

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hemoglobins; Humans; Postoperative

2019
Tranexamic acid can reduce blood loss in patients undergoing intertrochanteric fracture surgery: A meta-analysis.
    Medicine, 2019, Volume: 98, Issue:11

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hematoma; Hemoglobins; Hip Fractur

2019
Do we really need tranexamic acid in total hip arthroplasty? A meta-analysis of nineteen randomized controlled trials.
    Archives of orthopaedic and trauma surgery, 2013, Volume: 133, Issue:7

    Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Humans; Postoperative

2013
Do we really need tranexamic acid in total hip arthroplasty? A meta-analysis of nineteen randomized controlled trials.
    Archives of orthopaedic and trauma surgery, 2013, Volume: 133, Issue:7

    Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Humans; Postoperative

2013
Do we really need tranexamic acid in total hip arthroplasty? A meta-analysis of nineteen randomized controlled trials.
    Archives of orthopaedic and trauma surgery, 2013, Volume: 133, Issue:7

    Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Humans; Postoperative

2013
Do we really need tranexamic acid in total hip arthroplasty? A meta-analysis of nineteen randomized controlled trials.
    Archives of orthopaedic and trauma surgery, 2013, Volume: 133, Issue:7

    Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Humans; Postoperative

2013
Efficiency of tranexamic acid in perioperative blood loss in hip arthroplasty: a systematic literature review and meta-analysis.
    Revista espanola de anestesiologia y reanimacion, 2015, Volume: 62, Issue:5

    Topics: Adolescent; Adult; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Female;

2015
The effectiveness and safety of tranexamic acid in total hip or knee arthroplasty: a meta-analysis of 2720 cases.
    Transfusion medicine (Oxford, England), 2015, Volume: 25, Issue:3

    Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; Human

2015
The effectiveness and safety of tranexamic acid in total hip or knee arthroplasty: a meta-analysis of 2720 cases.
    Transfusion medicine (Oxford, England), 2015, Volume: 25, Issue:3

    Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; Human

2015
The effectiveness and safety of tranexamic acid in total hip or knee arthroplasty: a meta-analysis of 2720 cases.
    Transfusion medicine (Oxford, England), 2015, Volume: 25, Issue:3

    Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; Human

2015
The effectiveness and safety of tranexamic acid in total hip or knee arthroplasty: a meta-analysis of 2720 cases.
    Transfusion medicine (Oxford, England), 2015, Volume: 25, Issue:3

    Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; Human

2015
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
    Journal of perinatology : official journal of the California Perinatal Association, 2015, Volume: 35, Issue:10

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe

2015
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
    Journal of perinatology : official journal of the California Perinatal Association, 2015, Volume: 35, Issue:10

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe

2015
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
    Journal of perinatology : official journal of the California Perinatal Association, 2015, Volume: 35, Issue:10

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe

2015
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
    Journal of perinatology : official journal of the California Perinatal Association, 2015, Volume: 35, Issue:10

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe

2015
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
    Journal of perinatology : official journal of the California Perinatal Association, 2015, Volume: 35, Issue:10

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe

2015
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
    Journal of perinatology : official journal of the California Perinatal Association, 2015, Volume: 35, Issue:10

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe

2015
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
    Journal of perinatology : official journal of the California Perinatal Association, 2015, Volume: 35, Issue:10

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe

2015
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
    Journal of perinatology : official journal of the California Perinatal Association, 2015, Volume: 35, Issue:10

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe

2015
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
    Journal of perinatology : official journal of the California Perinatal Association, 2015, Volume: 35, Issue:10

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe

2015
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
    Journal of perinatology : official journal of the California Perinatal Association, 2015, Volume: 35, Issue:10

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe

2015
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
    Journal of perinatology : official journal of the California Perinatal Association, 2015, Volume: 35, Issue:10

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe

2015
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
    Journal of perinatology : official journal of the California Perinatal Association, 2015, Volume: 35, Issue:10

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe

2015
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
    Journal of perinatology : official journal of the California Perinatal Association, 2015, Volume: 35, Issue:10

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe

2015
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
    Journal of perinatology : official journal of the California Perinatal Association, 2015, Volume: 35, Issue:10

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe

2015
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
    Journal of perinatology : official journal of the California Perinatal Association, 2015, Volume: 35, Issue:10

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe

2015
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
    Journal of perinatology : official journal of the California Perinatal Association, 2015, Volume: 35, Issue:10

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe

2015
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
    Journal of perinatology : official journal of the California Perinatal Association, 2015, Volume: 35, Issue:10

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe

2015
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
    Journal of perinatology : official journal of the California Perinatal Association, 2015, Volume: 35, Issue:10

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe

2015
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
    Journal of perinatology : official journal of the California Perinatal Association, 2015, Volume: 35, Issue:10

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe

2015
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
    Journal of perinatology : official journal of the California Perinatal Association, 2015, Volume: 35, Issue:10

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe

2015
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
    Journal of perinatology : official journal of the California Perinatal Association, 2015, Volume: 35, Issue:10

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe

2015
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
    Journal of perinatology : official journal of the California Perinatal Association, 2015, Volume: 35, Issue:10

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe

2015
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
    Journal of perinatology : official journal of the California Perinatal Association, 2015, Volume: 35, Issue:10

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe

2015
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
    Journal of perinatology : official journal of the California Perinatal Association, 2015, Volume: 35, Issue:10

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe

2015
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
    Journal of perinatology : official journal of the California Perinatal Association, 2015, Volume: 35, Issue:10

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe

2015
Intravenous versus topical tranexamic acid in primary total hip replacement: A systemic review and meta-analysis.
    International journal of surgery (London, England), 2016, Volume: 32

    Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace

2016
Total hip replacement for hip fracture: Surgical techniques and concepts.
    Injury, 2016, Volume: 47, Issue:10

    Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Comorbidity; Elective Surgical Procedures;

2016
Efficiency and Safety of Intravenous Tranexamic Acid in Simultaneous Bilateral Total Knee Arthroplasty: A Systematic Review and Meta-analysis.
    Orthopaedic surgery, 2016, Volume: 8, Issue:3

    Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S

2016
Risks of harms using antifibrinolytics in cardiac surgery: systematic review and network meta-analysis of randomised and observational studies.
    BMJ (Clinical research ed.), 2012, Sep-11, Volume: 345

    Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced

2012
Minimising blood loss and transfusion in contemporary hip and knee arthroplasty.
    The Journal of bone and joint surgery. British volume, 2012, Volume: 94, Issue:11 Suppl A

    Topics: Anemia; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Bl

2012
Tranexamic acid and trauma: current status and knowledge gaps with recommended research priorities.
    Shock (Augusta, Ga.), 2013, Volume: 39, Issue:2

    Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Postoperative Complications; Randomized Controlled Tria

2013
Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding.
    The Annals of thoracic surgery, 1994, Volume: 58, Issue:6

    Topics: Aminocaproic Acid; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Procedures; Coronary Artery Byp

1994
Indications for antifibrinolytic therapy.
    Thrombosis et diathesis haemorrhagica, 1975, Dec-15, Volume: 34, Issue:3

    Topics: Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Coagulation Disorders; Disseminated Intrav

1975
Clinical application of inhibitors of fibrinolysis.
    Drugs, 1985, Volume: 29, Issue:3

    Topics: 4-Aminobenzoic Acid; Aminocaproic Acid; Angioedema; Antifibrinolytic Agents; Aprotinin; Blood Preser

1985

Trials

72 trials available for tranexamic acid and Complication, Postoperative

ArticleYear
Use of tranexamic acid in medial open wedge high tibial osteotomy.
    Archives of orthopaedic and trauma surgery, 2022, Volume: 142, Issue:9

    Topics: Hemoglobins; Humans; Osteoarthritis, Knee; Osteotomy; Pain, Postoperative; Postoperative Complicatio

2022
Effect of Sequential Intravenous and Oral Tranexamic Acid on Hemoglobin Drop After Total Knee Arthroplasty: A Randomized Controlled Trial.
    The Journal of bone and joint surgery. American volume, 2022, 01-19, Volume: 104, Issue:2

    Topics: Administration, Intravenous; Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Repl

2022
Intraoperative use of tranexamic acid to reduce blood loss during cytoreductive surgery for advanced ovarian cancer: A randomized controlled clinical trial.
    Acta obstetricia et gynecologica Scandinavica, 2023, Volume: 102, Issue:7

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical

2023
Effect of postoperative tranexamic acid on recurrence rate and complications in chronic subdural hematomas patients: preliminary results of a randomized controlled clinical trial.
    Neurosurgical review, 2023, Apr-18, Volume: 46, Issue:1

    Topics: Aged; Drainage; Hematoma, Subdural, Chronic; Humans; Postoperative Complications; Postoperative Peri

2023
Comparison of oral vs. combined topical/intravenous/oral tranexamic acid in the prevention of blood loss in total knee arthroplasty: A randomised clinical trial.
    Orthopaedics & traumatology, surgery & research : OTSR, 2019, Volume: 105, Issue:6

    Topics: Administration, Intravenous; Administration, Oral; Administration, Topical; Aged; Antifibrinolytic A

2019
Tranexamic acid or epsilon-aminocaproic acid in total joint arthroplasty? A randomized controlled trial.
    The bone & joint journal, 2019, Volume: 101-B, Issue:9

    Topics: Administration, Intravenous; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replace

2019
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
    The Journal of bone and joint surgery. American volume, 2019, Dec-04, Volume: 101, Issue:23

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin

2019
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
    The Journal of bone and joint surgery. American volume, 2019, Dec-04, Volume: 101, Issue:23

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin

2019
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
    The Journal of bone and joint surgery. American volume, 2019, Dec-04, Volume: 101, Issue:23

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin

2019
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
    The Journal of bone and joint surgery. American volume, 2019, Dec-04, Volume: 101, Issue:23

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin

2019
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
    The Journal of bone and joint surgery. American volume, 2019, Dec-04, Volume: 101, Issue:23

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin

2019
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
    The Journal of bone and joint surgery. American volume, 2019, Dec-04, Volume: 101, Issue:23

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin

2019
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
    The Journal of bone and joint surgery. American volume, 2019, Dec-04, Volume: 101, Issue:23

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin

2019
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
    The Journal of bone and joint surgery. American volume, 2019, Dec-04, Volume: 101, Issue:23

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin

2019
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
    The Journal of bone and joint surgery. American volume, 2019, Dec-04, Volume: 101, Issue:23

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin

2019
Combined Application of Dexamethasone and Tranexamic Acid to Reduce the Postoperative Inflammatory Response and Improve Functional Outcomes in Total Hip Arthroplasty.
    Orthopaedic surgery, 2020, Volume: 12, Issue:2

    Topics: Aged; Anti-Inflammatory Agents; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; C-Reactive

2020
Preoperative erythropoietin within a patient blood management program decreases both blood transfusion and postoperative anemia: a prospective observational study.
    Transfusion, 2020, Volume: 60, Issue:8

    Topics: Aged; Anemia; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Transfusion; Er

2020
Combined use of intravenous and topical tranexamic acid efficiently reduces blood loss in patients aged over 60 operated with a 2-level lumbar fusion.
    Journal of orthopaedic surgery and research, 2020, Aug-20, Volume: 15, Issue:1

    Topics: Administration, Topical; Age Factors; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra

2020
Tranexamic acid reduces blood cost in long-segment spinal fusion surgery: A randomized controlled study protocol.
    Medicine, 2020, 09-11, Volume: 99, Issue:37

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; Human

2020
Prophylactic use of tranexamic acid for prevention of bleeding during transbronchial lung biopsies - A randomized, double-blind, placebo-controlled trial.
    Respiratory medicine, 2020, Volume: 173

    Topics: Aged; Antifibrinolytic Agents; Biopsy; Blood Loss, Surgical; Bronchi; Double-Blind Method; Female; H

2020
Effect of Multiple Doses of Intravenous Tranexamic Acid on Perioperative Blood Loss in Total Knee Arthroplasty: A Randomized Controlled Study.
    Orthopaedic surgery, 2021, Volume: 13, Issue:1

    Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L

2021
Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomised, double-blinded, placebo-controlled trial.
    BJU international, 2022, Volume: 129, Issue:1

    Topics: Adolescent; Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Vol

2022
Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomised, double-blinded, placebo-controlled trial.
    BJU international, 2022, Volume: 129, Issue:1

    Topics: Adolescent; Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Vol

2022
Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomised, double-blinded, placebo-controlled trial.
    BJU international, 2022, Volume: 129, Issue:1

    Topics: Adolescent; Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Vol

2022
Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomised, double-blinded, placebo-controlled trial.
    BJU international, 2022, Volume: 129, Issue:1

    Topics: Adolescent; Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Vol

2022
Tranexamic acid attenuates early post-operative systemic inflammatory response and nutritional loss and avoids reduction of fibrinogen in total hip arthroplasty within an enhanced recovery after surgery pathway.
    International orthopaedics, 2021, Volume: 45, Issue:11

    Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Enhanced Recovery Aft

2021
Efficacy of tranexamic acid on side effects of rhinoplasty: A randomized double-blind study.
    Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery, 2017, Volume: 45, Issue:6

    Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Ecchymosis; Edema; Female

2017
Comparison of the Effect of Dexamethasone and Tranexamic Acid, Separately or in Combination on Post-Rhinoplasty Edema and Ecchymosis.
    Aesthetic plastic surgery, 2018, Volume: 42, Issue:1

    Topics: Adolescent; Adult; Analysis of Variance; Dexamethasone; Double-Blind Method; Drug Therapy, Combinati

2018
Multiple boluses of intravenous tranexamic acid to reduce hidden blood loss and the inflammatory response following enhanced-recovery primary total hip arthroplasty: a randomised clinical trial.
    The bone & joint journal, 2017, Volume: 99-B, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Biomarkers;

2017
Tranexamic acid as a local hemostasis method after dental extraction in patients on warfarin: a randomized controlled clinical study.
    Clinical oral investigations, 2018, Volume: 22, Issue:6

    Topics: Anticoagulants; Antifibrinolytic Agents; Female; Hemostatics; Humans; Male; Middle Aged; Oral Hemorr

2018
Synergistic effects of intravenous and intra-articular tranexamic acid on reducing hemoglobin loss in revision total knee arthroplasty: a prospective, randomized, controlled study.
    Transfusion, 2018, Volume: 58, Issue:4

    Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus

2018
Comparison between Intravenous Boluses versus Infusion of Tranexamic Acid (TXA) to Reduce Bleeding in Paediatric Cyanotic Congenital Heart Disease (CHD) Surgeries.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2018, Volume: 28, Issue:3

    Topics: Administration, Intravenous; Adolescent; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cardi

2018
OBTAIN E: outcome benefits of tranexamic acid in hip arthroplasty with enoxaparin: a randomised double-blinded controlled trial.
    Hip international : the journal of clinical and experimental research on hip pathology and therapy, 2019, Volume: 29, Issue:3

    Topics: Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Doubl

2019
Finding the Optimal Regimen for Oral Tranexamic Acid Administration in Primary Total Hip Arthroplasty: A Randomized Controlled Trial.
    The Journal of bone and joint surgery. American volume, 2019, Mar-06, Volume: 101, Issue:5

    Topics: Administration, Oral; Aged; Analysis of Variance; Antifibrinolytic Agents; Arthroplasty, Replacement

2019
Tranexamic Acid Use in Open Reduction and Internal Fixation of Fractures of the Pelvis, Acetabulum, and Proximal Femur: A Randomized Controlled Trial.
    Journal of orthopaedic trauma, 2019, Volume: 33, Issue:8

    Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; Femoral Fractures;

2019
The combined administration of systemic and topical tranexamic acid for total hip arthroplasty: Is it better than systemic?
    Acta orthopaedica et traumatologica turcica, 2019, Volume: 53, Issue:4

    Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R

2019
Different Effects of Intravenous, Topical, and Combined Application of Tranexamic Acid on Patients with Thoracolumbar Fracture.
    World neurosurgery, 2019, Volume: 127

    Topics: Administration, Intravenous; Administration, Topical; Adult; Antifibrinolytic Agents; Drug Therapy,

2019
Intra-articular Injection of Tranexamic Acid Reduced Postoperative Hemarthrosis in Arthroscopic Anterior Cruciate Ligament Reconstruction: A Prospective Randomized Study.
    Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association, 2019, Volume: 35, Issue:7

    Topics: Adult; Anterior Cruciate Ligament Reconstruction; Antifibrinolytic Agents; Arthroscopy; Female; Hema

2019
A Prospective Randomized Controlled Study of Oral Tranexamic Acid for the Prevention of Postinflammatory Hyperpigmentation After Q-Switched 532-nm Nd:YAG Laser for Solar Lentigines.
    Lasers in surgery and medicine, 2019, Volume: 51, Issue:10

    Topics: Administration, Oral; Adolescent; Adult; Aged; Dermatologic Agents; Double-Blind Method; Drug Admini

2019
Combined treatment of ulinastatin and tranexamic acid provides beneficial effects by inhibiting inflammatory and fibrinolytic response in patients undergoing heart valve replacement surgery.
    The heart surgery forum, 2013, Feb-01, Volume: 16, Issue:1

    Topics: Anti-Inflammatory Agents; Antifibrinolytic Agents; China; Comorbidity; Drug Therapy, Combination; Gl

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
Comparison of epsilon aminocaproic acid and tranexamic Acid in thoracic aortic surgery: clinical efficacy and safety.
    Journal of cardiothoracic and vascular anesthesia, 2013, Volume: 27, Issue:6

    Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aorta, Thoracic; Blood Loss, Surgical; Blood Tran

2013
The efficacy of tranexamic acid and corticosteroid on edema and ecchymosis in septorhinoplasty.
    Annals of plastic surgery, 2015, Volume: 74, Issue:4

    Topics: Adult; Anti-Inflammatory Agents; Antifibrinolytic Agents; Blood Loss, Surgical; Drug Administration

2015
Topical application of tranexamic acid reduces postoperative bleeding in open-heart surgery: myth or fact?
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2015, Volume: 25, Issue:3

    Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgica

2015
Intravenous versus intra-articular tranexamic acid in total knee arthroplasty: A double-blinded randomised controlled noninferiority trial.
    The Knee, 2016, Volume: 23, Issue:1

    Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace

2016
The Use of a Closed-Suction Drain in Revision Knee Arthroplasty May Not Be Necessary: A Prospective Randomized Study.
    The Journal of arthroplasty, 2016, Volume: 31, Issue:7

    Topics: Aged; Arthroplasty; Arthroplasty, Replacement, Knee; Blood Transfusion; Body Mass Index; Drainage; E

2016
Efficacy of preoperative administration of single high dose intravenous tranexamic acid in reducing blood loss in total knee arthroplasty: A prospective clinical study.
    Acta orthopaedica et traumatologica turcica, 2016, Volume: 50, Issue:4

    Topics: Administration, Intravenous; Aged; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Tran

2016
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
    The New England journal of medicine, 2017, 01-12, Volume: 376, Issue:2

    Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass

2017
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
    The New England journal of medicine, 2017, 01-12, Volume: 376, Issue:2

    Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass

2017
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
    The New England journal of medicine, 2017, 01-12, Volume: 376, Issue:2

    Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass

2017
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
    The New England journal of medicine, 2017, 01-12, Volume: 376, Issue:2

    Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass

2017
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
    The New England journal of medicine, 2017, 01-12, Volume: 376, Issue:2

    Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass

2017
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
    The New England journal of medicine, 2017, 01-12, Volume: 376, Issue:2

    Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass

2017
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
    The New England journal of medicine, 2017, 01-12, Volume: 376, Issue:2

    Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass

2017
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
    The New England journal of medicine, 2017, 01-12, Volume: 376, Issue:2

    Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass

2017
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
    The New England journal of medicine, 2017, 01-12, Volume: 376, Issue:2

    Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass

2017
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
    The New England journal of medicine, 2017, 01-12, Volume: 376, Issue:2

    Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass

2017
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
    The New England journal of medicine, 2017, 01-12, Volume: 376, Issue:2

    Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass

2017
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
    The New England journal of medicine, 2017, 01-12, Volume: 376, Issue:2

    Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass

2017
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
    The New England journal of medicine, 2017, 01-12, Volume: 376, Issue:2

    Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass

2017
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
    The New England journal of medicine, 2017, 01-12, Volume: 376, Issue:2

    Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass

2017
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
    The New England journal of medicine, 2017, 01-12, Volume: 376, Issue:2

    Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass

2017
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
    The New England journal of medicine, 2017, 01-12, Volume: 376, Issue:2

    Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass

2017
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
    The New England journal of medicine, 2017, 01-12, Volume: 376, Issue:2

    Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass

2017
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
    The New England journal of medicine, 2017, 01-12, Volume: 376, Issue:2

    Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass

2017
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
    The New England journal of medicine, 2017, 01-12, Volume: 376, Issue:2

    Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass

2017
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
    The New England journal of medicine, 2017, 01-12, Volume: 376, Issue:2

    Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass

2017
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
    The New England journal of medicine, 2017, 01-12, Volume: 376, Issue:2

    Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass

2017
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
    The New England journal of medicine, 2017, 01-12, Volume: 376, Issue:2

    Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass

2017
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
    The New England journal of medicine, 2017, 01-12, Volume: 376, Issue:2

    Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass

2017
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
    The New England journal of medicine, 2017, 01-12, Volume: 376, Issue:2

    Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass

2017
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
    The New England journal of medicine, 2017, 01-12, Volume: 376, Issue:2

    Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass

2017
Comparison of Enoxaparin and Rivaroxaban in Balance of Anti-Fibrinolysis and Anticoagulation Following Primary Total Knee Replacement: A Pilot Study.
    Medical science monitor : international medical journal of experimental and clinical research, 2017, Feb-08, Volume: 23

    Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Blood Coagulation; Drug Interactions; Enoxapa

2017
The blood sparing effect and the safety of aprotinin compared to tranexamic acid in paediatric cardiac surgery.
    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2009, Volume: 35, Issue:1

    Topics: Antifibrinolytic Agents; Aprotinin; Blood Component Transfusion; Blood Loss, Surgical; Drug Administ

2009
[Tranexamic acid reduces haematomas but not pain after total knee arthroplasty].
    Annales francaises d'anesthesie et de reanimation, 2011, Volume: 30, Issue:1

    Topics: Aged; Anesthesia, General; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Female; Hematom

2011
Tranexamic acid in adenotonsillectomy in children: a double-blind randomized clinical trial.
    International journal of pediatric otorhinolaryngology, 2012, Volume: 76, Issue:10

    Topics: Adenoidectomy; Antifibrinolytic Agents; Blood Loss, Surgical; Child; Child, Preschool; Double-Blind

2012
The comparative efficacies of intra-articular and IV tranexamic acid for reducing blood loss during total knee arthroplasty.
    Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA, 2013, Volume: 21, Issue:8

    Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Blood Loss, Sur

2013
Fibrinolytic inhibitors in off-pump coronary surgery: a prospective, randomized, double-blind TAP study (tranexamic acid, aprotinin, placebo).
    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2005, Volume: 28, Issue:4

    Topics: Aged; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Coronary Artery Bypass, Off-Pump; Cr

2005
Effect of topical tranexamic acid in open heart surgery.
    European journal of anaesthesiology, 2006, Volume: 23, Issue:5

    Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P

2006
Effect of topical tranexamic acid in open heart surgery.
    European journal of anaesthesiology, 2006, Volume: 23, Issue:5

    Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P

2006
Effect of topical tranexamic acid in open heart surgery.
    European journal of anaesthesiology, 2006, Volume: 23, Issue:5

    Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P

2006
Effect of topical tranexamic acid in open heart surgery.
    European journal of anaesthesiology, 2006, Volume: 23, Issue:5

    Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P

2006
Effect of topical tranexamic acid in open heart surgery.
    European journal of anaesthesiology, 2006, Volume: 23, Issue:5

    Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P

2006
Effect of topical tranexamic acid in open heart surgery.
    European journal of anaesthesiology, 2006, Volume: 23, Issue:5

    Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P

2006
Effect of topical tranexamic acid in open heart surgery.
    European journal of anaesthesiology, 2006, Volume: 23, Issue:5

    Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P

2006
Effect of topical tranexamic acid in open heart surgery.
    European journal of anaesthesiology, 2006, Volume: 23, Issue:5

    Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P

2006
Effect of topical tranexamic acid in open heart surgery.
    European journal of anaesthesiology, 2006, Volume: 23, Issue:5

    Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P

2006
Effect of topical tranexamic acid in open heart surgery.
    European journal of anaesthesiology, 2006, Volume: 23, Issue:5

    Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P

2006
Effect of topical tranexamic acid in open heart surgery.
    European journal of anaesthesiology, 2006, Volume: 23, Issue:5

    Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P

2006
Effect of topical tranexamic acid in open heart surgery.
    European journal of anaesthesiology, 2006, Volume: 23, Issue:5

    Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P

2006
Effect of topical tranexamic acid in open heart surgery.
    European journal of anaesthesiology, 2006, Volume: 23, Issue:5

    Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P

2006
Effect of topical tranexamic acid in open heart surgery.
    European journal of anaesthesiology, 2006, Volume: 23, Issue:5

    Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P

2006
Effect of topical tranexamic acid in open heart surgery.
    European journal of anaesthesiology, 2006, Volume: 23, Issue:5

    Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P

2006
Effect of topical tranexamic acid in open heart surgery.
    European journal of anaesthesiology, 2006, Volume: 23, Issue:5

    Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P

2006
Effect of topical tranexamic acid in open heart surgery.
    European journal of anaesthesiology, 2006, Volume: 23, Issue:5

    Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P

2006
Effect of topical tranexamic acid in open heart surgery.
    European journal of anaesthesiology, 2006, Volume: 23, Issue:5

    Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P

2006
Effect of topical tranexamic acid in open heart surgery.
    European journal of anaesthesiology, 2006, Volume: 23, Issue:5

    Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P

2006
Effect of topical tranexamic acid in open heart surgery.
    European journal of anaesthesiology, 2006, Volume: 23, Issue:5

    Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P

2006
Effect of topical tranexamic acid in open heart surgery.
    European journal of anaesthesiology, 2006, Volume: 23, Issue:5

    Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P

2006
Effect of topical tranexamic acid in open heart surgery.
    European journal of anaesthesiology, 2006, Volume: 23, Issue:5

    Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P

2006
Effect of topical tranexamic acid in open heart surgery.
    European journal of anaesthesiology, 2006, Volume: 23, Issue:5

    Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P

2006
Effect of topical tranexamic acid in open heart surgery.
    European journal of anaesthesiology, 2006, Volume: 23, Issue:5

    Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P

2006
Effect of topical tranexamic acid in open heart surgery.
    European journal of anaesthesiology, 2006, Volume: 23, Issue:5

    Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P

2006
[Aprotinin in cardiac surgery: more risks than usefulness?].
    Der Anaesthesist, 2006, Volume: 55, Issue:9

    Topics: Aminocaproates; Antifibrinolytic Agents; Aprotinin; Cardiac Surgical Procedures; Female; Hemostatics

2006
The hemostatic effect of tranexamic acid in conisatio colli uteri.
    Acta obstetricia et gynecologica Scandinavica, 1984, Volume: 63, Issue:1

    Topics: Adult; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Dilatation and Curettage; Double-Blind

1984
Use of an antifibrinolytic agent (tranexamic acid) and lateral sutures with laser conization of the cervix.
    Obstetrics and gynecology, 1984, Volume: 64, Issue:4

    Topics: Carcinoma in Situ; Cervix Uteri; Clinical Trials as Topic; Curettage; Cyclohexanecarboxylic Acids; F

1984
The effects on extraction wound healing of a new drug combination introduced for use in the prevention of post-extraction complications. A preliminary report.
    The British journal of oral surgery, 1981, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Alveolar Process; Anti-Infective Agents, Local; Antifibrinolytic Agents; Cyclohex

1981
The prevention of secondary haemorrhage after prostatectomy: the value of antifibrinolytic therapy.
    British journal of urology, 1980, Volume: 52, Issue:1

    Topics: Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Hemorrhage; Humans; Male; Postoperative Compl

1980
[The use of antifibrinolytics in heart surgery. 3 prospective studies].
    Cahiers d'anesthesiologie, 1993, Volume: 41, Issue:5

    Topics: Antifibrinolytic Agents; Aprotinin; Blood Platelets; Cardiac Surgical Procedures; Creatinine; Double

1993
The use of tranexamic acid to reduce postoperative bleeding following cardiac surgery: a double-blind randomized trial.
    The American surgeon, 1995, Volume: 61, Issue:7

    Topics: Blood Transfusion; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Coronary Artery Bypass; Doub

1995
Tranexamic acid significantly reduces blood loss associated with coronary revascularization.
    The Annals of thoracic surgery, 1995, Volume: 59, Issue:3

    Topics: Aged; Blood Coagulation Disorders; Blood Loss, Surgical; Cardiopulmonary Bypass; Erythrocyte Transfu

1995
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
    The British journal of surgery, 1994, Volume: 81, Issue:6

    Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me

1994
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
    The British journal of surgery, 1994, Volume: 81, Issue:6

    Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me

1994
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
    The British journal of surgery, 1994, Volume: 81, Issue:6

    Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me

1994
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
    The British journal of surgery, 1994, Volume: 81, Issue:6

    Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me

1994
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
    The British journal of surgery, 1994, Volume: 81, Issue:6

    Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me

1994
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
    The British journal of surgery, 1994, Volume: 81, Issue:6

    Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me

1994
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
    The British journal of surgery, 1994, Volume: 81, Issue:6

    Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me

1994
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
    The British journal of surgery, 1994, Volume: 81, Issue:6

    Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me

1994
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
    The British journal of surgery, 1994, Volume: 81, Issue:6

    Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me

1994
Prevention of postsurgical bleeding in oral surgery using tranexamic acid without dose modification of oral anticoagulants.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 1993, Volume: 51, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anticoagulants; Cardiovascular Diseases; Denta

1993
Tranexamic acid (Cyklokapron) is not necessary to reduce blood loss after coronary artery bypass operations.
    The Journal of thoracic and cardiovascular surgery, 1993, Volume: 105, Issue:1

    Topics: Adult; Aged; Blood Transfusion, Autologous; Body Surface Area; Coronary Artery Bypass; Early Ambulat

1993
Tranexamic acid reduces postbypass blood use: a double-blinded, prospective, randomized study of 210 patients.
    The Annals of thoracic surgery, 1996, Volume: 61, Issue:4

    Topics: Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiopulmonary Bypass; Double-Blind Method; Femal

1996
Tranexamic acid reduces blood loss and transfusion in reoperative cardiac surgery.
    Canadian journal of anaesthesia = Journal canadien d'anesthesie, 1997, Volume: 44, Issue:9

    Topics: Antifibrinolytic Agents; Blood Coagulation; Blood Loss, Surgical; Blood Transfusion; Blood Volume; C

1997
Prophylactic tranexamic acid and epsilon-aminocaproic acid for primary myocardial revascularization.
    The Annals of thoracic surgery, 1998, Volume: 65, Issue:2

    Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Coronary Artery

1998
Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty.
    Acta orthopaedica Scandinavica, 2000, Volume: 71, Issue:3

    Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Transfusion; Double-Blind Metho

2000
Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty.
    Acta orthopaedica Scandinavica, 2000, Volume: 71, Issue:3

    Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Transfusion; Double-Blind Metho

2000
Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty.
    Acta orthopaedica Scandinavica, 2000, Volume: 71, Issue:3

    Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Transfusion; Double-Blind Metho

2000
Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty.
    Acta orthopaedica Scandinavica, 2000, Volume: 71, Issue:3

    Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Transfusion; Double-Blind Metho

2000
Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty.
    Acta orthopaedica Scandinavica, 2000, Volume: 71, Issue:3

    Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Transfusion; Double-Blind Metho

2000
Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty.
    Acta orthopaedica Scandinavica, 2000, Volume: 71, Issue:3

    Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Transfusion; Double-Blind Metho

2000
Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty.
    Acta orthopaedica Scandinavica, 2000, Volume: 71, Issue:3

    Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Transfusion; Double-Blind Metho

2000
Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty.
    Acta orthopaedica Scandinavica, 2000, Volume: 71, Issue:3

    Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Transfusion; Double-Blind Metho

2000
Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty.
    Acta orthopaedica Scandinavica, 2000, Volume: 71, Issue:3

    Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Transfusion; Double-Blind Metho

2000
Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: effects on perioperative bleeding and allogeneic transfusions.
    The Journal of thoracic and cardiovascular surgery, 2000, Volume: 120, Issue:3

    Topics: Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Proced

2000
Tranexamic acid in alveolar sockets in the prevention of alveolitis sicca dolorosa.
    International journal of oral surgery, 1979, Volume: 8, Issue:6

    Topics: Adolescent; Adult; Age Factors; Alveolar Process; Contraceptives, Oral; Cyclohexanecarboxylic Acids;

1979
Double-blind trials with ethamsylate, batroxobin or tranexamic acid on blood loss after adenotonsillectomy.
    Acta clinica Belgica, 1977, Volume: 32, Issue:2

    Topics: Adenoidectomy; Batroxobin; Benzenesulfonates; Child; Clinical Trials as Topic; Cyclohexanecarboxylic

1977
Tranexamic acid in the preoperative management of ruptured intracranial aneurysms.
    Surgical neurology, 1978, Volume: 10, Issue:1

    Topics: Adult; Aged; Antifibrinolytic Agents; Clinical Trials as Topic; Constriction, Pathologic; Cyclohexan

1978
A double-blind study on the influence of tranexamic acid on the intraocular pressure and the central corneal thickness after trabeculectomy for glaucoma simplex.
    Acta ophthalmologica, 1978, Volume: 56, Issue:6

    Topics: Aged; Antifibrinolytic Agents; Clinical Trials as Topic; Cornea; Cyclohexanecarboxylic Acids; Double

1978
Postoperative venous thrombosis in benign prostatic disease. A study of 316 patients, using the 125I-fibrinogen uptake test.
    Scandinavian journal of urology and nephrology, 1975, Issue:27 suppl

    Topics: Acute Disease; Aged; Clinical Trials as Topic; Dextrans; Fibrinogen; Heparin; Humans; Male; Middle A

1975
Tranexamic acid (AMCA) and late hyphaema. A double blind study in cataract surgery.
    Acta ophthalmologica, 1976, Volume: 54, Issue:4

    Topics: Administration, Oral; Cataract Extraction; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Dr

1976
[Result of an antifibrinolytic treatment using tranexamic acid for the reduction of blood-loss during and after tonsillectomy].
    Schweizerische medizinische Wochenschrift, 1977, Jun-04, Volume: 107, Issue:22

    Topics: Adolescent; Adult; Cyclohexanecarboxylic Acids; Drug Evaluation; Female; Hemorrhage; Humans; Male; M

1977
The effect of warm heart surgery on postoperative bleeding.
    The Journal of thoracic and cardiovascular surgery, 1992, Volume: 103, Issue:6

    Topics: Aminocaproic Acid; Analysis of Variance; Blood Loss, Surgical; Blood Transfusion; Chi-Square Distrib

1992
Prophylactic tranexamic acid decreases bleeding after cardiac operations.
    The Journal of thoracic and cardiovascular surgery, 1990, Volume: 99, Issue:1

    Topics: Adult; Aged; Blood Coagulation Factors; Blood Coagulation Tests; Coronary Artery Bypass; Cyclohexane

1990
Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study.
    Acta neurochirurgica, 1990, Volume: 102, Issue:1-2

    Topics: Adult; Aged; Brain Ischemia; Cerebrovascular Circulation; Clinical Trials as Topic; Cyclohexanecarbo

1990
No additive effect of tranexamic acid and naproxen on corneal deswelling. A study on oedema after uncomplicated intracapsular cataract extraction with anterior chamber lens implantation.
    Acta ophthalmologica, 1986, Volume: 64, Issue:3

    Topics: Aged; Cataract Extraction; Clinical Trials as Topic; Cornea; Corneal Diseases; Cyclohexanecarboxylic

1986
Antifibrinolytic therapy for prevention of hemorrhage during surgery of the thyroid gland.
    Klinische Wochenschrift, 1987, Mar-16, Volume: 65, Issue:6

    Topics: Adenoma; Adult; Aged; Aged, 80 and over; Cyclohexanecarboxylic Acids; Double-Blind Method; Fibrinoly

1987

Other Studies

112 other studies available for tranexamic acid and Complication, Postoperative

ArticleYear
Effect of an Elevated Preoperative International Normalized Ratio on Transfusion and Complications in Primary Total Hip Arthroplasty with the Enhanced Recovery after Surgery Protocol.
    Orthopaedic surgery, 2022, Volume: 14, Issue:1

    Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Transfusion; Enhanced Re

2022
Tranexamic acid protects against implant-associated infection by reducing biofilm formation.
    Scientific reports, 2022, 03-22, Volume: 12, Issue:1

    Topics: Animals; Antifibrinolytic Agents; Biofilms; Blood Loss, Surgical; Humans; Mice; Postoperative Compli

2022
Tranexamic Acid Associated With Less Wound Complications in Ankle and Hindfoot Surgery: Level III, Retrospective Cohort Study.
    The Journal of the American Academy of Orthopaedic Surgeons, 2022, Aug-15, Volume: 30, Issue:16

    Topics: Ankle; Arthrodesis; Foot; Humans; Postoperative Complications; Retrospective Studies; Tranexamic Aci

2022
[Total hip arthroplasty:topical issues and new concepts].
    Zhongguo gu shang = China journal of orthopaedics and traumatology, 2022, 07-25, Volume: 35, Issue:7

    Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Humans; Postoperative Complications; Tranex

2022
Effectiveness of prophylactic doses of tranexamic acid in reducing hemorrhagic events in sleeve gastrectomy.
    Langenbeck's archives of surgery, 2022, Volume: 407, Issue:7

    Topics: Gastrectomy; Humans; Laparoscopy; Obesity, Morbid; Postoperative Complications; Postoperative Hemorr

2022
Predictors and complications of blood transfusion in rheumatoid arthritis patients undergoing total joint arthroplasty.
    Clinical rheumatology, 2023, Volume: 42, Issue:1

    Topics: Antifibrinolytic Agents; Arthritis, Rheumatoid; Arthroplasty, Replacement, Hip; Blood Loss, Surgical

2023
Intravenous tranexamic acid is associated with an increased risk of pulmonary embolism following sarcoma resection.
    Journal of surgical oncology, 2023, Volume: 128, Issue:5

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Postoperative Complications; Pulmonary Emboli

2023
Efficacy of local infiltration of tranexamic acid in subcutaneous surgery: A protocol from a single medical center.
    Medicine, 2023, Sep-01, Volume: 102, Issue:35

    Topics: Fibrinolytic Agents; Hematoma; Humans; Postoperative Complications; Retrospective Studies; Surgeons;

2023
The value of tranexamic acid for patients with preoperative anemia in primary total knee arthroplasty.
    European journal of medical research, 2019, Aug-12, Volume: 24, Issue:1

    Topics: Aged; Anemia; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Chi-Square Distribution; Female

2019
Tranexamic acid and convulsive seizures after off-pump coronary artery bypass surgery: the role of renal insufficiency.
    Interactive cardiovascular and thoracic surgery, 2019, 12-01, Volume: 29, Issue:6

    Topics: Adult; Aged; Antifibrinolytic Agents; Coronary Artery Bypass, Off-Pump; Female; Glomerular Filtratio

2019
Postoperative ultrasound evaluation for deep vein thrombosis after knee replacement surgery performed with tranexamic acid.
    Minerva anestesiologica, 2020, Volume: 86, Issue:2

    Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; Humans

2020
What's New in Adult Reconstructive Knee Surgery.
    The Journal of bone and joint surgery. American volume, 2020, 01-15, Volume: 102, Issue:2

    Topics: Analgesics, Opioid; Anesthesia; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss

2020
Bronchoscopic delivery of aminocaproic acid as a treatment for pulmonary bleeding: A case series.
    Pulmonary pharmacology & therapeutics, 2020, Volume: 60

    Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Bronchoscopy; Female; Hemoptysis; Hemorrhage; Huma

2020
Simultaneous Bilateral Total Knee Arthroplasty Becomes Safer after Institution of Optimal Perioperative Management: A Longitudinal Cohort Study.
    The journal of knee surgery, 2021, Volume: 34, Issue:9

    Topics: Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Humans; Longitudinal Studies; Postoperative C

2021
Tranexamic acid and convulsive seizures after isolated coronary artery bypass surgery: the role of cardiopulmonary bypass and renal function.
    Interactive cardiovascular and thoracic surgery, 2020, 04-01, Volume: 30, Issue:4

    Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Coronary Artery Bypass; Female; Glomerular Fi

2020
Intravenous Tranexamic Acid Safely and Effectively Reduces Transfusion Rates in Revision Total Knee Arthroplasties.
    The Journal of bone and joint surgery. American volume, 2020, Mar-04, Volume: 102, Issue:5

    Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty,

2020
Peri-operative administration of tranexamic acid in lower limb arthroplasty: a multicentre, prospective cohort study.
    Anaesthesia, 2020, Volume: 75, Issue:8

    Topics: Aged; Aged, 80 and over; Anemia; Antifibrinolytic Agents; Arthroplasty, Replacement; Arthroplasty, R

2020
Consideration on the Use of Tranexamic Acid in Rhytidectomy.
    Aesthetic surgery journal, 2020, 08-14, Volume: 40, Issue:9

    Topics: Double-Blind Method; Humans; Pilot Projects; Postoperative Complications; Rhytidoplasty; Tranexamic

2020
Effect of Tranexamic Acid on Wound Complications and Blood Loss in Total Ankle Arthroplasty.
    Foot & ankle international, 2020, Volume: 41, Issue:9

    Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Ankle; Blood Loss, Surgical; Cohort Studie

2020
Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events.
    Plastic and reconstructive surgery, 2020, Volume: 146, Issue:2

    Topics: Adult; Antifibrinolytic Agents; Breast; Breast Implants; Breast Neoplasms; Dose-Response Relationshi

2020
Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events.
    Plastic and reconstructive surgery, 2020, Volume: 146, Issue:2

    Topics: Adult; Antifibrinolytic Agents; Breast; Breast Implants; Breast Neoplasms; Dose-Response Relationshi

2020
Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events.
    Plastic and reconstructive surgery, 2020, Volume: 146, Issue:2

    Topics: Adult; Antifibrinolytic Agents; Breast; Breast Implants; Breast Neoplasms; Dose-Response Relationshi

2020
Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events.
    Plastic and reconstructive surgery, 2020, Volume: 146, Issue:2

    Topics: Adult; Antifibrinolytic Agents; Breast; Breast Implants; Breast Neoplasms; Dose-Response Relationshi

2020
Finding the optimal control level of intraoperative blood pressure in no tourniquet primary total knee arthroplasty combine with tranexamic acid: a retrospective cohort study which supports the enhanced recovery strategy.
    Journal of orthopaedic surgery and research, 2020, Aug-25, Volume: 15, Issue:1

    Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Pressure

2020
Does tourniquet use decrease blood loss following primary total knee arthroplasty in Jehovah's Witness patients?
    Joint diseases and related surgery, 2020, Volume: 31, Issue:3

    Topics: Aged; Anesthesia; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Fe

2020
Is continuation of anti-platelet treatment safe for elective total hip arthroplasty patients?
    Archives of orthopaedic and trauma surgery, 2020, Volume: 140, Issue:12

    Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Aspirin; Blood Los

2020
Tranexamic Acid in Infantile Craniosynostosis Surgery: Friend or Foe?
    Plastic and reconstructive surgery, 2020, Volume: 146, Issue:5

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Craniosynostoses; Female; Humans;

2020
Use of tranexamic acid is not associated with complications following bipolar hemiarthroplasty for metastatic disease.
    Journal of surgical oncology, 2021, Volume: 123, Issue:4

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Femoral Neoplasms; Femur Neck; Follow-Up Stud

2021
Is there a role of tranexamic acid in rheumatoid arthritis with total knee arthroplasty? Findings from a multicenter prospective cohort study in China.
    Archives of orthopaedic and trauma surgery, 2021, Volume: 141, Issue:3

    Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C

2021
Surgical Correction of Scoliosis in Children with Severe Congenital Heart Disease and Palliated Single Ventricle Physiology.
    Spine, 2021, Jul-15, Volume: 46, Issue:14

    Topics: Adolescent; Adult; Child; Cohort Studies; Female; Heart Defects, Congenital; Heart Ventricles; Human

2021
The Effects of Intraoperative Local Tranexamic Acid on Periorbital Edema and Ecchymosis in Septorhinoplasty.
    The Journal of craniofacial surgery, 2021, Sep-01, Volume: 32, Issue:6

    Topics: Ecchymosis; Edema; Humans; Postoperative Complications; Rhinoplasty; Tranexamic Acid

2021
Effect of Tranexamic Acid Administration on Postoperative Ecchymosis and Edema in Excision of Lipomas.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2021, 03-01, Volume: 47, Issue:3

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Dermatologic Surgical

2021
Hockey: a pain in the butt! Isolated superior gluteal artery rupture following blunt pelvic trauma - an unusual case.
    Annals of the Royal College of Surgeons of England, 2021, Volume: 103, Issue:3

    Topics: Aneurysm, False; Antifibrinolytic Agents; Buttocks; Computed Tomography Angiography; Embolization, T

2021
Tranexamic acid in patients with current or former cancer undergoing hip and knee arthroplasty.
    Journal of surgical oncology, 2021, Volume: 123, Issue:8

    Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Fema

2021
[Tranexamic Acid Reduces the Incidence of Heterotopic Ossifications after Elective Primary Total Hip Arthroplasty].
    Acta chirurgiae orthopaedicae et traumatologiae Cechoslovaca, 2021, Volume: 88, Issue:1

    Topics: Arthroplasty, Replacement, Hip; Female; Humans; Incidence; Ossification, Heterotopic; Postoperative

2021
Risk Factors for Increased Surgical Drain Output After Transforaminal Lumbar Interbody Fusion.
    World neurosurgery, 2021, Volume: 151

    Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Lumbar Verteb

2021
BET 2: Topical tranexamic acid in postcircumcision bleeding.
    Emergency medicine journal : EMJ, 2021, Volume: 38, Issue:4

    Topics: Administration, Topical; Antifibrinolytic Agents; Child, Preschool; Circumcision, Male; Hemorrhage;

2021
Tranexamic Acid Was Not Associated with Increased Complications in High-Risk Patients with Hip Fracture Undergoing Arthroplasty.
    The Journal of bone and joint surgery. American volume, 2021, 10-20, Volume: 103, Issue:20

    Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Female; Hip

2021
Effect and safety of topical application of tranexamic acid to reduce perioperative blood loss in elderly patients with intertrochanteric fracture undergoing PFNA.
    Medicine, 2021, Aug-27, Volume: 100, Issue:34

    Topics: Administration, Topical; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blo

2021
Intraoperative tranexamic acid is associated with postoperative stroke in patients undergoing cardiac surgery.
    PloS one, 2017, Volume: 12, Issue:5

    Topics: Adult; Coronary Artery Bypass; Female; Humans; Intraoperative Care; Male; Middle Aged; Postoperative

2017
Fibrinolysis in Living Donor Liver Transplantation Recipients Evaluated Using Thromboelastometry: Impact on Mortality.
    Transplantation proceedings, 2017, Volume: 49, Issue:9

    Topics: Adult; Aged; Antifibrinolytic Agents; Female; Fibrinolysis; Hepatic Artery; Humans; Incidence; Liver

2017
Commentary on: "Comparison of the Effect of Dexamethasone and Tranexamic Acid, Separately or in Combination on Post-rhinoplasty and Edema and Ecchymosis".
    Aesthetic plastic surgery, 2018, Volume: 42, Issue:1

    Topics: Dexamethasone; Ecchymosis; Edema; Humans; Osteotomy; Postoperative Complications; Rhinoplasty; Trane

2018
Improved Early Postoperative Range of Motion in Total Knee Arthroplasty Using Tranexamic Acid: A Retrospective Analysis.
    The journal of knee surgery, 2019, Volume: 32, Issue:2

    Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Case-Control Studies

2019
Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy.
    Obstetrics and gynecology, 2018, Volume: 131, Issue:5

    Topics: Aged; Antifibrinolytic Agents; Blood Transfusion; Endometrial Neoplasms; Female; Humans; Laparotomy;

2018
Tranexamic Acid in Pertrochanteric Femoral Fracture: Is it a Safe Drug or Not?
    Folia medica, 2018, Mar-01, Volume: 60, Issue:1

    Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Transfusion; Female; Fracture Fixation, Intr

2018
The Effect of Preoperative Administration of Intravenous Tranexamic Acid During Revision Hip Arthroplasty: A Retrospective Study.
    The Journal of bone and joint surgery. American volume, 2018, Sep-05, Volume: 100, Issue:17

    Topics: Acetabulum; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood

2018
Early morbidity and mortality after single-stage bilateral total knee replacement.
    Orthopaedics & traumatology, surgery & research : OTSR, 2018, Volume: 104, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss

2018
Perioperative Tranexamic Acid Treatment and Risk of Cardiovascular Events or Death After Total Hip Arthroplasty: A Population-Based Cohort Study from National Danish Databases.
    The Journal of bone and joint surgery. American volume, 2018, Oct-17, Volume: 100, Issue:20

    Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Cardiovascular Diseases; Cohort Studi

2018
Reducing Blood Loss in Revision Total Hip and Knee Arthroplasty: Tranexamic Acid Is Effective in Aseptic Revisions and in Second-Stage Reimplantations for Periprosthetic Infection.
    BioMed research international, 2018, Volume: 2018

    Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female;

2018
The Efficacy and Safety of Prophylactic Intravenous Tranexamic Acid on Perioperative Blood Loss in Patients Treated with Posterior Lumbar Interbody Fusion.
    World neurosurgery, 2019, Volume: 125

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion, Autologous; Body Mass Index; Bone

2019
Immunohistochemical Grading of Epidural Fibrosis with CD105 Antibody.
    World neurosurgery, 2019, Volume: 125

    Topics: Animals; Antibodies, Monoclonal; Antifibrinolytic Agents; Biomarkers; Endoglin; Epidural Space; Fibr

2019
Aprotinin versus tranexamic acid in children undergoing cardiac surgery: an observational study.
    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2019, Oct-01, Volume: 56, Issue:4

    Topics: Antifibrinolytic Agents; Aprotinin; Blood Transfusion; Cardiac Surgical Procedures; Child, Preschool

2019
The necessity of routine postoperative laboratory tests in enhanced recovery after surgery for primary hip and knee arthroplasty: A retrospective cohort study protocol.
    Medicine, 2019, Volume: 98, Issue:18

    Topics: Adult; Anemia; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, K

2019
Efficacy and safety of tranexamic acid in geriatric hip fracture with hemiarthroplasty: a retrospective cohort study.
    BMC musculoskeletal disorders, 2019, Jun-28, Volume: 20, Issue:1

    Topics: Age Factors; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Erythrocyte Tra

2019
The efficacy and safety of tranexamic acid for reducing blood loss following simultaneous bilateral total knee arthroplasty: a multicenter retrospective study.
    BMC musculoskeletal disorders, 2019, Jul-12, Volume: 20, Issue:1

    Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L

2019
Postoperative seizure in a neurosurgical patient: Should tranexamic acid be on the differential?
    Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2013, Volume: 60, Issue:5

    Topics: Cardiac Surgical Procedures; Female; Humans; Male; Postoperative Complications; Seizures; Tranexamic

2013
[A case of postoperative convulsive seizure following tranexamic acid infusion during aortic valve replacement].
    Masui. The Japanese journal of anesthesiology, 2013, Volume: 62, Issue:2

    Topics: Aged, 80 and over; Aortic Valve; Humans; Male; Postoperative Complications; Seizures; Tranexamic Aci

2013
[Intravenous administration of tranexamic acid to decrease bleeding and transfusion in knee and hip prosthetic surgery: is it safe and cost-effective?].
    Medicina clinica, 2013, Sep-07, Volume: 141, Issue:5

    Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Cost-Benefit

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:8 Suppl

    Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss,

2013
Postoperative cerebral arterial thrombosis following cranial surgery in an infant.
    Paediatric anaesthesia, 2013, Volume: 23, Issue:11

    Topics: Antifibrinolytic Agents; Cerebral Angiography; Craniosynostoses; Craniotomy; Humans; Infant; Intracr

2013
Oral versus intravenous tranexamic acid in enhanced-recovery primary total hip and knee replacement: results of 3000 procedures.
    The bone & joint journal, 2013, Volume: 95-B, Issue:11

    Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antifibrinolytic

2013
Oral versus intravenous tranexamic acid in enhanced-recovery primary total hip and knee replacement: results of 3000 procedures.
    The bone & joint journal, 2013, Volume: 95-B, Issue:11

    Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antifibrinolytic

2013
Oral versus intravenous tranexamic acid in enhanced-recovery primary total hip and knee replacement: results of 3000 procedures.
    The bone & joint journal, 2013, Volume: 95-B, Issue:11

    Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antifibrinolytic

2013
Oral versus intravenous tranexamic acid in enhanced-recovery primary total hip and knee replacement: results of 3000 procedures.
    The bone & joint journal, 2013, Volume: 95-B, Issue:11

    Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antifibrinolytic

2013
Measurement of tranexamic acid serum concentrations in a 7-month-old infant with clinical seizures after open heart surgery.
    Pediatric neurology, 2014, Volume: 51, Issue:2

    Topics: Antifibrinolytic Agents; Cardiac Surgical Procedures; Humans; Infant; Postoperative Complications; S

2014
Radial artery pseudoaneurysm: a rare complication after arthroscopic treatment of a volar wrist ganglion in a hemophilia patient.
    Chirurgie de la main, 2014, Volume: 33, Issue:5

    Topics: Adult; Aneurysm, False; Antifibrinolytic Agents; Arthroscopy; Ganglion Cysts; Hemophilia A; Humans;

2014
Tranexamic acid and fibrinogen restore clotting in vitro and in vivo in cardiac thrombus associated hyperfibrinolysis with overt bleedings.
    Thrombosis and haemostasis, 2014, Volume: 112, Issue:5

    Topics: Adenocarcinoma; Aged; Anemia; Antifibrinolytic Agents; Antineoplastic Combined Chemotherapy Protocol

2014
[Changes of the hemostasis system in patients with obturation jaundice caused by choledocholithiasis, and possibilities of their correction with the help of miniinvasive operative interventions].
    Klinichna khirurhiia, 2014, Issue:8

    Topics: Anticoagulants; Antifibrinolytic Agents; Blood Coagulation Disorders; Choledocholithiasis; Drug Admi

2014
Evaluating the safety and efficacy of tranexamic acid administration in pediatric cranial vault reconstruction.
    The Journal of craniofacial surgery, 2015, Volume: 26, Issue:1

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child, Preschool; Cohort Studies;

2015
TXA in combat casualty care--does it adversely affect extremity reconstruction and flap thrombosis rates?
    Military medicine, 2015, Volume: 180, Issue:3 Suppl

    Topics: Adult; Antifibrinolytic Agents; Arm Injuries; Female; Follow-Up Studies; Free Tissue Flaps; Humans;

2015
Tranexamic Acid Decreases Incidence of Blood Transfusion in Simultaneous Bilateral Total Knee Arthroplasty.
    The Journal of arthroplasty, 2015, Volume: 30, Issue:12

    Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus

2015
Low dose tranexamic acid reduces blood transfusion rate after total knee arthroplasty: A population-based study in Taiwan.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2017, Volume: 116, Issue:1

    Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L

2017
A protocol for management of blood loss in surgical treatment of peritoneal malignancy by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Transfusion medicine (Oxford, England), 2016, Volume: 26, Issue:2

    Topics: Blood Component Transfusion; Blood Loss, Surgical; Cytoreduction Surgical Procedures; Factor VIII; F

2016
Effect of Antifibrinolytic Therapy on Complications, Thromboembolic Events, Blood Product Utilization, and Fusion in Adult Spinal Deformity Surgery.
    Spine, 2016, Jul-15, Volume: 41, Issue:14

    Topics: Adult; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male;

2016
Implementation of a Tranexamic Acid Protocol to Reduce Blood Loss During Cranial Vault Remodeling for Craniosynostosis.
    The Journal of craniofacial surgery, 2016, Volume: 27, Issue:6

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Craniosynostoses; Hemorrhage; Humans; Infant; Postope

2016
Influence of single-dose intravenous tranexamic acid on total hip replacement : A study on transfusions, collateral complications, and readmissions.
    Der Orthopade, 2017, Volume: 46, Issue:4

    Topics: Aged; Antifibrinolytic Agents; Argentina; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Bloo

2017
C1-esterase inhibitor for short-term prophylaxis in a patient with hereditary angioedema with normal C1 inhibitor function.
    Journal of clinical anesthesia, 2016, Volume: 35

    Topics: Adult; Angioedemas, Hereditary; Antifibrinolytic Agents; Complement C1 Inactivator Proteins; Complem

2016
Aprotinin is not associated with postoperative renal impairment after primary coronary surgery.
    The Annals of thoracic surgery, 2008, Volume: 86, Issue:1

    Topics: Acute Kidney Injury; Aged; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Case-Control Studies;

2008
Safety and efficacy of tranexamic acid compared with aprotinin in thoracic aortic surgery with deep hypothermic circulatory arrest.
    Journal of cardiothoracic and vascular anesthesia, 2010, Volume: 24, Issue:1

    Topics: Antifibrinolytic Agents; Aortic Diseases; Aprotinin; Blood Transfusion; Circulatory Arrest, Deep Hyp

2010
The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery.
    Anesthesia and analgesia, 2010, Jan-01, Volume: 110, Issue:1

    Topics: Aged; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Procedures; Cardiop

2010
High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.
    Anesthesia and analgesia, 2010, Feb-01, Volume: 110, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Proc

2010
High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.
    Anesthesia and analgesia, 2010, Feb-01, Volume: 110, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Proc

2010
High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.
    Anesthesia and analgesia, 2010, Feb-01, Volume: 110, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Proc

2010
High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.
    Anesthesia and analgesia, 2010, Feb-01, Volume: 110, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Proc

2010
Successful control of massive gastrointestinal bleeding following umbilical cord blood transplantation (UCBT) by use of recombinant activated factor VII (rFVIIa) and octreotide infusion.
    Pediatric hematology and oncology, 2010, Volume: 27, Issue:1

    Topics: beta-Thalassemia; Bone Marrow Transplantation; Cord Blood Stem Cell Transplantation; Delayed Graft F

2010
[Perioperative management of a patient complicated with Quincke's edema].
    Masui. The Japanese journal of anesthesiology, 2010, Volume: 59, Issue:4

    Topics: Aneurysm, Ruptured; Angioedema; Chlorpheniramine; Craniotomy; Humans; Intracranial Aneurysm; Intubat

2010
Dental surgery with minimal factor support in the inherited bleeding disorder population at the Alfred Hospital.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2011, Volume: 17, Issue:1

    Topics: Antifibrinolytic Agents; Blood Coagulation Disorders, Inherited; Blood Coagulation Factors; Cellulos

2011
Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis.
    Critical care (London, England), 2010, Volume: 14, Issue:4

    Topics: Aged; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Procedures; Cardiop

2010
Tranexamic Acid in cardiac surgery and postoperative seizures: a case report series.
    The heart surgery forum, 2010, Volume: 13, Issue:4

    Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Cardiac Surgical Procedures; Cohort Studies; Coron

2010
Seizures after open heart surgery: comparison of ε-aminocaproic acid and tranexamic acid.
    Journal of cardiothoracic and vascular anesthesia, 2011, Volume: 25, Issue:1

    Topics: Aged; Aminocaproic Acid; Anesthesia; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical

2011
Conference discussion: Removal of aprotinin from low-dose aprotinin/tranexamic acid antifibrinolytic therapy increases transfusion requirements in cardiothoracic surgery.
    Interactive cardiovascular and thoracic surgery, 2011, Volume: 12, Issue:2

    Topics: Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Cardiopulmonary Bypass;

2011
Seizures after adult cardiac surgery.
    Journal of cardiothoracic and vascular anesthesia, 2011, Volume: 25, Issue:4

    Topics: Aminocaproic Acid; Antifibrinolytic Agents; Cardiac Surgical Procedures; Female; Humans; Male; Posto

2011
[Transfusion requirements, morbidity and mortality in cardiac surgery and the use of antifibrinolytic agents: a comparison of aprotinin and tranexamic acid].
    Revista espanola de anestesiologia y reanimacion, 2011, Volume: 58, Issue:3

    Topics: Aged; Antifibrinolytic Agents; Aprotinin; Blood Transfusion; Cardiac Surgical Procedures; Cross-Sect

2011
"Seizing" the opportunity to understand antifibrinolytic drugs.
    Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2012, Volume: 59, Issue:1

    Topics: Cardiac Surgical Procedures; Female; Humans; Male; Postoperative Complications; Seizures; Tranexamic

2012
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass.
    The Annals of thoracic surgery, 2012, Volume: 93, Issue:1

    Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence

2012
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass.
    The Annals of thoracic surgery, 2012, Volume: 93, Issue:1

    Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence

2012
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass.
    The Annals of thoracic surgery, 2012, Volume: 93, Issue:1

    Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence

2012
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass.
    The Annals of thoracic surgery, 2012, Volume: 93, Issue:1

    Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence

2012
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass.
    The Annals of thoracic surgery, 2012, Volume: 93, Issue:1

    Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence

2012
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass.
    The Annals of thoracic surgery, 2012, Volume: 93, Issue:1

    Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence

2012
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass.
    The Annals of thoracic surgery, 2012, Volume: 93, Issue:1

    Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence

2012
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass.
    The Annals of thoracic surgery, 2012, Volume: 93, Issue:1

    Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence

2012
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass.
    The Annals of thoracic surgery, 2012, Volume: 93, Issue:1

    Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence

2012
Seizures following cardiac surgery: the impact of tranexamic acid and other risk factors.
    Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2012, Volume: 59, Issue:1

    Topics: Aged; Aged, 80 and over; Anticonvulsants; Antifibrinolytic Agents; Cardiac Surgical Procedures; Coho

2012
Tranexamic acid and coronary surgery.
    Anesthesia and analgesia, 2004, Volume: 98, Issue:1

    Topics: Antifibrinolytic Agents; Cardiac Surgical Procedures; Coronary Vessels; Humans; Intraoperative Compl

2004
Aprotinin and renal risk in cardiac surgery.
    Transfusion, 2006, Volume: 46, Issue:12

    Topics: Aprotinin; Cardiac Surgical Procedures; Hemostatics; Humans; Kidney; Postoperative Complications; Ri

2006
An anti-inflammatory role for tranexamic acid in cardiac surgery?
    Critical care (London, England), 2008, Volume: 12, Issue:1

    Topics: Antifibrinolytic Agents; Cardiac Surgical Procedures; Cytokines; Humans; Inflammation Mediators; Pos

2008
Effect of aprotinin on renal dysfunction in patients undergoing on-pump and off-pump cardiac surgery: a retrospective observational study.
    Lancet (London, England), 2008, Feb-09, Volume: 371, Issue:9611

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surg

2008
[Coagulative changes in gynecologic surgery. Clinical and therapeutic evaluation].
    Recenti progressi in medicina, 1980, Volume: 68, Issue:4

    Topics: Adult; Aged; Anesthesia; Aprotinin; Blood Coagulation Disorders; Disseminated Intravascular Coagulat

1980
The value of activated coagulation time in monitoring heparin therapy during extracorporeal circulation.
    Scandinavian journal of thoracic and cardiovascular surgery, 1984, Volume: 18, Issue:2

    Topics: Aged; Antithrombin III; Blood Coagulation Tests; Coronary Artery Bypass; Dose-Response Relationship,

1984
Effects of tranexamic acid and local fibrin deposition of fibrinolysis and granulation tissue formation in preformed cavities.
    Thrombosis research, 1984, Jan-01, Volume: 33, Issue:1

    Topics: Animals; Cyclohexanecarboxylic Acids; Drug Evaluation, Preclinical; Drug Implants; Fibrin; Fibrinoly

1984
A new combination of drugs intended to be used as a preventive measure for the postextraction complications. A preliminary report.
    International journal of oral surgery, 1981, Volume: 10, Issue:1

    Topics: Adolescent; Adult; Cyclohexanecarboxylic Acids; Dibucaine; Drug Combinations; Dry Socket; Humans; Hy

1981
[Behavior of tranexamic acid as an antiflogistic in oral surgery].
    Rivista italiana di stomatologia, 1981, Volume: 50, Issue:5

    Topics: Anti-Inflammatory Agents; Cyclohexanecarboxylic Acids; Humans; Mouth Diseases; Postoperative Complic

1981
The use of frusemide and epsilon-amino-caproic-acid in transurethral prostatectomy. a review after 7 years.
    British journal of urology, 1982, Volume: 54, Issue:4

    Topics: Aged; Aminocaproates; Aminocaproic Acid; Furosemide; Hemorrhage; Humans; Male; Postoperative Complic

1982
[Changes in the course after spontaneous subarachnoid hemorrhage from the neurological point of view].
    Fortschritte der Neurologie-Psychiatrie, 1982, Volume: 50, Issue:8

    Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Postoperative Complications; Subarachnoid Hemorrhage

1982
The use of tranexamic acid in cardiac operations.
    The Journal of thoracic and cardiovascular surgery, 1994, Volume: 107, Issue:5

    Topics: Aminocaproic Acid; Cardiopulmonary Bypass; Coronary Artery Bypass; Hemorrhage; Humans; Postoperative

1994
Tranexamic acid after bypass: too late to help?
    The Journal of thoracic and cardiovascular surgery, 1994, Volume: 107, Issue:5

    Topics: Cardiopulmonary Bypass; Coronary Artery Bypass; Hemorrhage; Humans; Postoperative Complications; Tra

1994
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications.
    Thrombosis and haemostasis, 1993, Aug-02, Volume: 70, Issue:2

    Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P

1993
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications.
    Thrombosis and haemostasis, 1993, Aug-02, Volume: 70, Issue:2

    Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P

1993
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications.
    Thrombosis and haemostasis, 1993, Aug-02, Volume: 70, Issue:2

    Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P

1993
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications.
    Thrombosis and haemostasis, 1993, Aug-02, Volume: 70, Issue:2

    Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P

1993
Tranexamic acid reduces blood loss after knee arthroplasty.
    The Journal of bone and joint surgery. British volume, 1996, Volume: 78, Issue:6

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Knee Prosthesis; Postoperative Complications;

1996
Cardiopulmonary by-pass in a patient with acquired C1 inhibitor deficiency.
    The International journal of artificial organs, 1997, Volume: 20, Issue:3

    Topics: Aged; Anabolic Agents; Angioedema; Antifibrinolytic Agents; Aprotinin; Autoimmune Diseases; Calcium

1997
Effects of tranexamic acid and aprotinin, two antifibrinolytic drugs, on PAF-induced plasma extravasation in unanesthetized rats.
    Inflammation, 2000, Volume: 24, Issue:5

    Topics: Animals; Antifibrinolytic Agents; Aorta; Aprotinin; Bronchi; Capillary Leak Syndrome; Capillary Perm

2000
Is tranexamic acid safe in patients undergoing coronary endarterectomy?
    The Annals of thoracic surgery, 2001, Volume: 71, Issue:5

    Topics: Aged; Coronary Artery Bypass; Coronary Artery Disease; Endarterectomy; Female; Graft Occlusion, Vasc

2001
Transurethral electroresection of prostatic adenoma. Early results.
    Scandinavian journal of urology and nephrology, 1976, Volume: 10, Issue:1

    Topics: Aged; Blood Transfusion; Electrosurgery; Humans; Male; Middle Aged; Postoperative Complications; Pro

1976
Management of late corneal graft problems.
    Acta ophthalmologica, 1978, Volume: 56, Issue:6

    Topics: Adrenal Cortex Hormones; Adult; Aged; Corneal Transplantation; Cyclohexanecarboxylic Acids; Female;

1978
Complications of antifibrinolysis therapy after prostatectomy.
    British journal of urology, 1979, Volume: 51, Issue:3

    Topics: Cyclohexanecarboxylic Acids; Fibrinolysis; Humans; Male; Postoperative Complications; Prostatectomy;

1979
[Preventive use of AMCHA in tonsillectomies under general anesthesia. Clinical evaluation].
    Minerva anestesiologica, 1976, Volume: 42, Issue:10

    Topics: Adolescent; Adult; Anesthesia, General; Child; Child, Preschool; Cyclohexanecarboxylic Acids; Drug E

1976
[Possibilities of the use of an inhibitor of hemolysis (AMCHA), by rectal and vaginal administration, for gynecological hemorrhages].
    Minerva ginecologica, 1975, Volume: 27, Issue:4

    Topics: Adolescent; Adult; Aged; Blood Coagulation Disorders; Child; Cyclohexanecarboxylic Acids; Female; He

1975
Acquired C1 esterase inhibitor deficiency.
    Anaesthesia, 1986, Volume: 41, Issue:8

    Topics: Angioedema; Complement C1 Inactivator Proteins; Female; Humans; Mesenteric Vascular Occlusion; Middl

1986
[Further clinical experimental research on the anti-inflammatory action of tranexamic acid in oral surgery].
    Dental Cadmos, 1985, Apr-30, Volume: 53, Issue:7

    Topics: Anti-Inflammatory Agents; Cefazolin; Cyclohexanecarboxylic Acids; Humans; Mouth; Postoperative Compl

1985